

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using bw model

Run on: January 26, 2005, 12:54:26 ; Search time 191 Seconds

(without alignment)
777.208 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MSGAVLRVLRNRPQAVLM.....SVLQDQMPYQNAQAQVZA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : UniProt 02:*

1: uniprot_sprot:*

2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|--------|-------------|--------|----|-------------|
| 1 | 1386 | 98.1 | 273 | 1 | GFR4_RAT |
| 2 | 1075.5 | 76.1 | 260 | 1 | GFR4_MOUSE |
| 3 | 767.5 | 54.3 | 259 | 1 | GFR4_HUMAN |
| 4 | 585.5 | 41.4 | 431 | 1 | GFR4_CHICK |
| 5 | 476.5 | 33.7 | 481 | 2 | Q98T78 |
| 6 | 476.5 | 33.7 | 481 | 2 | AAK11261 |
| 7 | 471 | 33.3 | 330 | 2 | Q922A2 |
| 8 | 469 | 33.2 | 358 | 2 | Q922A3 |
| 9 | 469 | 33.2 | 444 | 2 | Q792X9 |
| 10 | 469 | 33.2 | 464 | 2 | Q35977 |
| 11 | 465 | 32.9 | 463 | 1 | GFR2_MOUSE |
| 12 | 465 | 32.9 | 463 | 2 | Q920Y3 |
| 13 | 465 | 32.9 | 465 | 1 | GFR1_HUMAN |
| 14 | 464 | 32.8 | 331 | 2 | Q725C2 |
| 15 | 464 | 32.8 | 463 | 2 | Q35252 |
| 16 | 464 | 32.8 | 468 | 1 | GFR1_MOUSE |
| 17 | 464 | 32.8 | 468 | 2 | Q35246 |
| 18 | 463 | 32.8 | 469 | 1 | GFR1_CHICK |
| 19 | 462 | 32.7 | 463 | 1 | Q35748 |
| 20 | 462 | 32.7 | 464 | 1 | GFR2_HUMAN |
| 21 | 462 | 32.7 | 464 | 2 | AAH41688 |
| 22 | 462 | 32.7 | 464 | 2 | GFR1_RAT |
| 23 | 460.5 | 32.6 | 465 | 1 | GFR2_CHICK |
| 24 | 459 | 32.5 | 472 | 2 | Q98T79 |
| 25 | 459 | 32.5 | 472 | 2 | AAK11260 |
| 26 | 434.5 | 30.8 | 495 | 2 | Q6T5C3 |
| 27 | 434.5 | 30.8 | 495 | 2 | AAK9464 |
| 28 | 366.5 | 25.9 | 397 | 2 | AAH66202 |
| 29 | 364.5 | 25.8 | 385 | 2 | Q9R2D0 |
| 30 | 364.5 | 25.8 | 397 | 1 | GFR3_MOUSE |
| 31 | 363 | 25.7 | 222 | 2 | Q9Q2G2 |

| | | | | | | |
|----|-------|------|------|---|------------|--------------------|
| 32 | 361 | 25.5 | 369 | 2 | AA089396 | AA089396 homo sapi |
| 33 | 361 | 25.5 | 400 | 1 | GFR3_HUMAN | 060609 homo sapien |
| 34 | 361 | 25.5 | 400 | 2 | AA089356 | AA089356 homo sapi |
| 35 | 253.5 | 17.9 | 225 | 2 | Q9QWK2 | Q9QWK2 mus musculu |
| 36 | 209.5 | 14.8 | 109 | 2 | Q8JG58 | Q8JG58 ambystoma m |
| 37 | 184.5 | 13.1 | 394 | 2 | Q6UXV0 | Q6UXV0 homo sapien |
| 38 | 184.5 | 13.1 | 394 | 2 | AA088565 | AA088565 homo sapi |
| 39 | 172.5 | 12.2 | 1219 | 2 | Q95XG5 | Q95XG5 caenorhabd |
| 40 | 167 | 11.8 | 393 | 2 | Q6S0B0 | Q6S0B0 mus musculu |
| 41 | 167 | 11.8 | 393 | 2 | AA513632 | AA513632 mus muscu |
| 42 | 153.5 | 10.9 | 502 | 2 | Q7QDE4 | Q7QDE4 anopheles g |
| 43 | 131.5 | 9.3 | 744 | 2 | Q8NH02 | Q8NH02 homo sapien |
| 44 | 130.5 | 9.2 | 3718 | 1 | LM45_MOUSE | 061001 mus musculu |
| 45 | 130.5 | 9.2 | 3775 | 2 | Q7PMF9 | Q7PMF9 anopheles g |

ALIGNMENTS

RESULT 1

| ID | Accession | Standard | PRT | AA |
|----|--|----------|-----|----|
| AC | GFR4_RAT | | | |
| AD | Q9EP12; Q9EP13; | | | |
| DT | 10-OCT-2003 (Rel. 42, Created) | | | |
| DT | 10-OCT-2003 (Rel. 42, Last sequence update) | | | |
| DT | 05-JUL-2004 (Rel. 44, Last annotation update) | | | |
| DE | GNF Family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4) | | | |
| DE | (perlephrin receptor). | | | |
| GN | Name=Gfr4; | | | |
| OS | Rattus norvegicus (Rat). | | | |
| OC | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; | | | |
| OC | Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus. | | | |
| OX | NCBI_TaxId=10116; | | | |
| RN | [1] | | | |
| RP | SEQUENCE FROM N.A. (ISOFORMS A AND B), AND VARIANT ARG-257. | | | |
| RC | TISSUE=Brain, Heart, and Kidney; | | | |
| RX | MEDLINE=20564314; PubMed=10958791; DOI=10.1074/jbc.M003867200; | | | |
| RA | Maure S., Cik M., Hoefnagel E., Nozrat C.A., Van der Linden I., | | | |
| RA | Scott R., Van Gompel P., Lesage A.S.J., Verhaesselt P., Ibanez C.F., | | | |
| RA | Gordon R.D.; | | | |
| RT | "Mammalian GFRalpha-4, a divergent member of the GFRalpha family of | | | |
| RT | coreceptors for Glial cell line-derived neurotrophic factor family | | | |
| RT | ligands, is a receptor for the neurotrophic factor perlephrin."; | | | |
| RL | J. Biol. Chem. 275:39427-39434(2000). | | | |
| CC | - FUNCTION: Receptor for perlephrin. Mediates the GDNF-induced | | | |
| CC | autophosphorylation and activation of the RT receptor. May be | | | |
| CC | important in C-cell development and, in the postnatal development | | | |
| CC | of the adrenal medulla. | | | |
| CC | - SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor | | | |
| CC | (isoform A). Secreted (isoform B) (Potential). | | | |
| CC | - ALTERNATIVE PRODUCTS: | | | |
| CC | Event=Alternative splicing; Named isoforms=2; | | | |
| CC | Comment=Additional isoforms seem to exist; | | | |
| CC | Name=A; | | | |
| CC | Isoid=Q9EP12-1; Sequence=Displayed; | | | |
| CC | Name=B; | | | |
| CC | Isoid=Q9EP12-2; Sequence=VSP_007230; | | | |
| CC | - TISSUE SPECIFICITY: Weakly expressed in heart, brain and testis. | | | |
| CC | - SIMILARITY: Belongs to the GDNF family. | | | |
| CC | This SWISS-PROT entry is copyright. It is produced through a collaboration | | | |
| CC | between the Swiss Institute of Bioinformatics and the EMBL outstation- | | | |
| CC | the European Bioinformatics Institute. There are no restrictions on its | | | |
| CC | use by non-profit institutions as long as its content is in no way | | | |
| CC | modified and this statement is not removed. Usage by and for commercial | | | |
| CC | entities requires a license agreement (See http://www.isb-sib.ch/announce/ | | | |
| CC | or send an email to license@sib-sib.ch). | | | |
| DR | EMBL; AJ294475; CAC16420.1; - | | | |
| DR | EMBL; AJ294476; CAC16421.1; - | | | |
| DR | RGD; 620503; Gfr4. | | | |
| DR | InterPro; IPR003438; GDNF_receptor. | | | |
| DR | Pfam; PF02351; GDNF; 1. | | | |

DR PRINTS: PRO1316; GDNF RECEPTOR.
 KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 KM Polymorphism; Receptor; Signal.
 FT SIGNAL 1 ? Potential.
 FT CHAIN ? 250 GDNF family receptor alpha 4.
 FT PROPEP 251 273 Removed in mature form (Potential).
 FT CARBOHYD 192 192 N-linked (GlcNAc...) (Potential).
 FT LIPID 250 250 GPI-anchor amidated asparagine (Potential).
 FT VARSPLIC 253 273 CCFWVSSMSITLALALQALL -> QAKVEA (in isoform B).
 FT VARIANT 257 257 /FTId=VSP_007230.
 FT SEQUENCE 272 AA; 29682 MW; EOBH76ABE2AC6B04 CRC64; W -> R (in 50% of the molecules).
 Query Match 98.1%; Score 1386; DB 1; Length 273;
 Best Local Similarity 100.0%; Pred. No. 1.2e-109;
 Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLGSAVLRVNERPGQAVLMSLGQSGASSTEGRCVEAAEACTADECCQQRSEVVAQ 60
 DB 1 MLGSAVLRVNERPGQAVLMSLGQSGASSTEGRCVEAAEACTADECCQQRSEVVAQ 60
 QY 61 CLGSAWPGSGSCVRSRCRRALRRFPARGPALTHALFCGCEGPACAERRRQTPAPAC 120
 DB 61 CLGSAWPGSGSCVRSRCRRALRRFPARGPALTHALFCGCEGPACAERRRQTPAPAC 120
 QY 121 FSGQLAPSPCLKRLDCESSRRCPRLFAFQASCAPAPSGDCEEGSPCLRAVAGL 180
 DB 121 FSGQLAPSPCLKRLDCESSRRCPRLFAFQASCAPAPSGDCEEGSPCLRAVAGL 180
 QY 181 VGVTVENVLDNV SARVAWPGSCASGNRRECEAPFKLFTNPCLDGAQADSPQSV 240
 DB 181 VGVTVENVLDNV SARVAWPGSCASGNRRECEAPFKLFTNPCLDGAQADSPQSV 240
 QY 241 LQOQWNPYQWAG 252
 DB 241 LQOQWNPYQWAG 252

RESULT 2
 ID GFR4 MOUSE STANDARD; PRT; 260 AA.
 AC Q9JUT2; Q9JUT3; Q9JUT4; Q9JUT6; Q9JUT7; Q9JUT8;
 DT 10-OCT-2003 (Rel. 42, Created)
 DT 10-OCT-2003 (Rel. 42, Last sequence update)
 DE 05-JUL-2004 (Rel. 44, Last annotation update)
 DE GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)
 GN (Perephrin receptor).
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A. (ISOFORMS A1; A2; A3; B1; B2 AND B3).
 RC TISSUE=thyroid;
 RX MEDLINE=20319126; PubMed=10680579; DOI=10.1006/mcne.2000.0845;
 RA Lindahl M., Timmusk T., Rossi J., Saarma M., Atrakshen M.S.;
 RT "Expression and alternative splicing of mouse Gfr4 suggest roles in
 RL endocrine cell development.";
 RL Mol. Cell. Neurosci. 15:522-533 (2000).
 -1- FUNCTION: Receptor for perephrin. Mediates the GDNF-induced
 CC autophosphorylation and activation of the RET receptor. May be
 CC important in C-cell development and, in the postnatal development
 CC of the adrenal medulla.
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
 CC (isoforms a1 and b1). Secreted (isoforms a3 and b3) (Potential).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=6;
 CC Comment=Additional isoforms seem to exist. Tissue-specific and,
 CC developmentally regulated splicing;
 CC Name=a1;

CC IsoId=Q9JUT2-1; Sequence=Displayed;
 CC Name=a2;
 CC IsoId=Q9JUT2-2; Sequence=VSP_007227;
 CC Name=a3;
 CC IsoId=Q9JUT2-3; Sequence=VSP_007226, VSP_007229;
 CC Name=b1;
 CC IsoId=Q9JUT2-4; Sequence=VSP_007226;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Name=b2;
 CC IsoId=Q9JUT2-5; Sequence=VSP_007226, VSP_007227;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC Name=b3;
 CC IsoId=Q9JUT2-6; Sequence=VSP_007226, VSP_007228, VSP_007229;
 CC Note=Alternative N-terminal. Probably non-functional;
 CC -1- TISSUE SPECIFICITY: Expressed in many tissues including adrenal
 CC medulla, brain neurons, with highest levels in the cerebral
 CC cortex and hippocampus. Moderate levels found in the gut circular
 CC muscle and myenteric ganglia as well as in other peripheral
 CC ganglia, including the sensory dorsal root and trigeminal as well
 CC as superior cervical and sympathetic chain ganglia. Isoform a1,
 CC isoform a2, isoform b1 and isoform b2 are exclusively found in the
 CC thyroid, parathyroid and pituitary glands.
 CC -1- DEVELOPMENTAL STAGE: Expressed in several tissues at different
 CC embryonic and postnatal stages such as the condensing mesenchyme
 CC of developing bones and developing nervous system. Expressed in
 CC the developing pituitary gland from E16 and in developing thyroid
 CC C-cells from E14. In the ventral spinal cord, levels decline
 CC before birth. In the parathyroid, levels first detected in 3-to 6-
 CC week-old mice with high expression. In the adrenal medulla,
 CC expressed only in newborn, postnatal (P08) and adult mice. Isoform
 CC a1 and isoform b1 are preferentially expressed in 3-week-old
 CC thyroid, isoform a2 and isoform b2 in newborn and 6-week-old
 CC thyroid glands as well as in postnatal adrenal and pituitary
 CC glands.
 CC -1- SIMILARITY: Belongs to the GDNF family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; AJ276870; CAB89690.1; -;
 CC EMBL; AJ276871; CAB89691.1; -;
 CC EMBL; AJ276872; CAB89692.1; -;
 CC EMBL; AJ276514; CAB89687.1; -;
 CC EMBL; AJ276515; CAB89688.1; -;
 CC EMBL; AJ276516; CAB89689.1; -;
 CC MGD; MGI:1341873; Gfr4.
 CC InterPro; IPR003438; GDNF_receptor.
 CC Pfam; PF02351; GDNF_1.
 CC PRINTS; PRO1316; GDNF RECEPTOR.
 CC DR Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
 CC KW Receptor; Signal.
 FT SIGNAL 1 23
 FT CHAIN 24 237 GDNF family receptor alpha 4.
 FT PROPEP 238 260 Removed in mature form (Potential).
 FT CARBOHYD 184 184 N-linked (GlcNAc...) (Potential).
 FT LIPID 237 237 GPI-anchor amidated threonine (Potential).
 FT VARSPLIC 1 17 MACHESALLLILLILS -> MLRAHLMDEPQAIPLGLT
 FT GSGQGS (in isoform b1, isoform b2 and
 FT isoform b3).
 FT VARSPLIC 245 260 /FTId=VSP_007226.
 FT VMLVATLALALQALL -> ARHEWPKSWKQSLFCGNA
 FT OGVLAVCTHCPSGSPALIRNNRRHS (in isoform
 FT a2 and isoform b2).
 FT VARSPLIC 138 190 /FTId=VSP_007227.
 FT PRLTFAQSCAPAPSGRCEEGSPCLRAVAGLIGTVTVT
 FT PNYLDNV SARVA -> CVRAGAGPLTVRARAGVSLPSR
 FT PHALPRAPATVARRRGARVVCASQAS (in isoform

| | | | |
|----|---------------------------|---|---|
| FT | | a3 and isoform b3). | |
| FT | | /FTId=VSP_007228. | |
| FT | VARSPLIC | 191 | 260 Missing (in isoform a3 and isoform b3). |
| FT | | | /FTId=VSP_007229. |
| SO | SEQUENCE | 260 AA; 27990 MW; 2679BBC789E38075 CRC64; | |
| | Query Match | 76.1%; Score 1075.5; DB 1; Length 260; | |
| | Best Local Similarity | 89.6%; Pred. NO. 2.6e-83; | |
| | Matches 198; Conservative | 7; Mismatches 13; Indels 3; Gaps 1; | |
| Oy | | 27 GSASSTEGNRCVEAENACTADQCQQLSEYVAOCLAGRA---GNGPGSCVYSRRCRALR | 83 |
| Dd | | 16 GSASTPDGNRCVDAAEAECTADBERCQQLSEYVARCLGRAPAGRGRRPGCGCRSRRLALR | 75 |
| Oy | | 84 RFPARGPALTHALLFCGCCEGPACERRRQTFAFAPCAFSGPOLADPSCCLKPLDRCESRR | 143 |
| Dd | | 76 RFPARGPALTHALLFCGCCEGSACERRRQTFAFAPCAFSGPLVPSPCLEPERCERSRL | 135 |
| Oy | | 144 CRPLRFAPAQACAPAPSGRDGPEEGSGRCIRAYAGLVGTWTPPYLUNVSARVAPMGCC | 203 |
| Dd | | 136 CRPLRLTAQAQACAPAPSGSRDRCPBGGSGRCILKAVGLIGTWTTPYLUNVSARVAPMGCC | 195 |
| Oy | | 204 EASGNRECECAFRLFTFRNPCLDAIQAOPSSQPSVODQ | 244 |
| Dd | | 196 AASGNRECECAFRLFTFRNPCLDAIQAOPSLQPSVODQ | 236 |
| | RESULT 3 | | |
| | GFR4_HUMAN | STANDARD: | PRT; 299 AA. |
| ID | | OG6Z27; O9H191; O9H192; | |
| AC | | 10-OCT-2003 (Rel. 42, created) | |
| DT | | 10-OCT-2003 (Rel. 42, last annotation update) | |
| DT | | 05-JUL-2004 (Rel. 44, last annotation update) | |
| DE | | GNDF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4) | |
| DE | | (Persephin receptor). | |
| GN | | Name=GFR4; | |
| OS | | Homo sapiens (Human). | |
| OC | | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; | |
| OC | | Mammalia; Euteria; Primates; Catarrhini; Homidae; Homo. | |
| OX | | NCBI_Taxid=9606; | |
| RN | | [1] | |
| RP | | SEQUENCE FROM N.A. (ISOFORMS GFRALPHA4A, GFRALPHA4B AND GFRALPHA4C), | |
| RP | | AND GPI-ANCHOR. | |
| RC | | TISSUE=Thyroid; | |
| RC | | MEDLINE=21153758; PubMed=1116144; DOI=10.1074/jbc.M008279200; | |
| RA | | Lindahl M., Poteryaev D., Yu L., Arunae U., Timmuck T., Bongarzoni I., | |
| RA | | Afiello A., Pierotti M.A., Alzakenen M.S., Saarna M., | |
| RT | | "Human gliat cell line-derived neurotrophic factor receptor alpha4 is | |
| RT | | the receptor for persephin and is predominantly expressed in normal | |
| RT | | and malignant thyroid medullary cells." | |
| RL | | J. Biol. Chem. 276:9344-9351(2001). | |
| RN | | [2] | |
| RP | | SEQUENCE FROM N.A. (ISOFORM GFRALPHA4A). | |
| RA | | Zhou B., Levinson B., Gitlschier J.; | |
| RA | | Submitted (Apr-2000) to the EMBL/Genbank/DBJ databases. | |
| RN | | [3] | |
| RP | | SEQUENCE FROM N.A. | |
| RX | | MEDLINE=21638479; PubMed=11780052; DOI=10.1038/414865a; | |
| RA | | DeJonkas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., | |
| RA | | Jones M., Stavrides G., Almeida J.P., Babbage A.K., Baggailey C.L., | |
| RA | | Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., | |
| RA | | Beasley O.P., Bird C.F., Blakey S.E., Bridgeman A.M., Brown A.J., | |
| RA | | Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P., | |
| RA | | Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., | |
| RA | | Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., | |
| RA | | Coulson A., Coville G.U., Deedman R., Dhali P.D., Dunn M., | |
| RA | | Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., | |
| RA | | Griffham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.B., | |
| RA | | Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., | |
| RA | | Huckle E., Hunt A.R., Hunt S.E., Jekesch K., Johnson C.M., Johnson D., | |
| RA | | Kay M.P., Kimberley A.M., King A., Knight A., Laird G.K., Lawlor S., | |
| RA | | Lehvaeslahti M.H., Leversteina M.A., Lloyd C., Lloyd D.M., Lovell J.D., | |

| Query Match | Best Local Similarity | Score | DB 1 | Length | 299 |
|-------------|-----------------------|-------------------|------------------------|--------|-----|
| 54.3% | 62.5% | Pred. NO. 4.3e-57 | | | |
| Sequence | 299 AA | 31669 MM | 844388332FF10801 CRC64 | | |
| VARSPPLIC | 132 | 182 | | | |
| VARSPPLIC | 183 | 299 | | | |
| SEQUENCE | 299 AA | 31669 MM | 844388332FF10801 CRC64 | | |

Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

QY 27 GSASTBGRCTEAAEACTADDECCOQLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFF 86
 DB 16 GSASSVGGRCTVDAEACTADARCORLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFF 72
 QY 87 ARGPALTHALLFCGCEGPACERRRORFAPACAFSGQALPSPCLKXLDCESSRCR- 145
 DB 73 ARGPALTHALLFCGCEGPACERRRORFAPACAFSGQALPSPCLKXLDCESSRCR- 132
 QY 146 -----PRLFAQASCAPAPGSDGCEPCEGRCRAY 177
 DB 133 ARAAAGPWRGWRGRLSPARPPAQAASPPGLSGLVHPSAQRRRLPAGPGRPLPARLRGP 192
 QY 178 AGL-VGTAVTPNYLDNVASARVAPMGCGEASGNRECEAPRKLFTTRNPCLDGAIOAPDSS 236
 DB 193 RGVAVAGTAVTPNYLDNVASARVAPMGCGEASGNRECEAPRKLFTTRNPCLDGAIOAPDSS 252
 QY 237 QPSVYLDQGNP 247
 DB 253 WPPVLLDQGNP 263

RESULT 4

QY GFR4 CHICK STANDARD; PRT; 431 AA.
 AC 093512;
 DT 10-OCT-2003 (Rel. 42, Created)
 DT 10-OCT-2003 (Rel. 42, Last sequence update)
 DT 05-JUN-2004 (Rel. 44, Last annotation update)
 DE GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4).
 GN Name=GFR4;
 OS Gallus gallus (Chicken)
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 OC Gallus.
 ON NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Embryonic brain;
 RX MEDLINE=98313402; PubMed=9647690;
 RA Thompson J., Doxakis E., Pinon L.G.P., Strachan P., Bui-Bello A.,
 RA Myatt S., Buchan V.L., Davies A.M., Strachan P., Bui-Bello A.,
 RT GFRalpha-4 a new GDNF family receptor.";
 RL Mol. Cell. Neurosci. 11:117-126(1998).
 RN [2]
 RP IDENTIFICATION OF LIGAND.
 RX MEDLINE=98421156; PubMed=9740802;
 RA Enokido Y., de Sauvage F., Hongo J.-A., Ninkina N., Rosenthal A.,
 RA Buchan V.L., Davies A.M., Hongo J.-A., Ninkina N., Rosenthal A.,
 RT GFRalpha-4 and the tyrosine kinase Ret form a functional receptor
 RT complex for persephin.";
 RL Curr. Biol. 8:1019-1022(1998).
 CC -1- FUNCTION: Receptor for persephin. Mediates the GDNF-induced
 CC autophosphorylation and activation of the RET receptor (By
 CC similarity).
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By
 CC similarity).
 CC -1- DEVELOPMENTAL STAGE: Expressed in muscle, kidney, brain, stomach
 CC and intestine at E6. Levels increase in the brain from E6 to E18,
 CC and decrease in muscle and intestine. Levels in the kidney remain
 CC constant. From E10, expression also found in heart, lung, skin and
 CC liver. Levels in the liver increase dramatically at E18. At E18,
 CC central nervous system, the spinal cord expressed the highest
 CC levels. Lower levels found in the medulla oblongata, pons,
 CC cerebellum and midbrain, and very low levels in the forebrain.
 CC -1- SIMILARITY: Belongs to the GDNF family.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; AF045162; AAC36464.1; -
 DR InterPro; IPR003438; GDNF_receptor.
 DR Pfam; PF02351; GDNF, 1.
 DR PRINTS; PR01316; GDNFRECEPTOR.
 KM Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.
 FT SIGNAL 1
 FT CHAIN 1
 FT PROPEP 404 403 GDNF family receptor alpha 4.
 FT CARBOHYD 180 180 Removed in mature form (Potential).
 FT CARBOHYD 236 236 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 308 308 N-linked (GlcNAc...) (Potential).
 FT CARBOHYD 339 339 N-linked (GlcNAc...) (Potential).
 FT LIPID 403 403 GPI-anchor amidated serine (Potential).
 SQ SEQUENCE 431 AA; 47964 MW; 3EDD945D3C4E71B CRC64;
 Query Match 41.4%; Score 585.5; DB 1; Length 431;
 Best Local Similarity 47.4%; Pred. No. 1,8e-41;
 Matches 110; Conservative 37; Mismatches 72; Indels 13; Gaps 4;

QY 32 TEGNRCEAAEACTADDECCOQLRSEYVAQCLGRAGMRGPGSCVRSRCPALRRFFANGPP 91
 DB 140 TQVNRCLDAARACNVDEMCORLRTEYVSFCIRRLA--RADTCNRSKCHKLRKFFDRAVP 197
 QY 92 ALTHALLFCGCEGPACERRRORFAPACAFSGQALPSPCLKXLDCESSRCRPRAPAF 151
 DB 198 EYTHALLFCPEEDPNCARRRQRTVPACSYSSKE--KNCCLAPLDSGRENVYCSRAEF 255
 QY 152 QASCAPAPGSDGCEPCEGRCRAYAGLVGTAVTPNYLDNVASARVAPMGCGEASGNRR 211
 DB 256 QNQCPSLOTASGGRGRDYSVAACLAATYGIIGSPITPYINDNSSTAPWCTCANSGRQE 315
 QY 212 ECEAPRKLFTTRNPCLDGAIOAFD-----SSQSPV--LDQGNPYNQAQA 254
 DB 316 ECBSFLHFTDNLVCLQNAIDQFNGTYLNAATAPSSPTTOMYKQERNANRA 367

RESULT 5

QY G98TT8 PRELIMINARY; PRT; 481 AA.
 AC 098TT8;
 DT 01-JUN-2001 (TREMBLrel. 17, Created)
 DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)
 DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
 DE GDNF family receptor alpha-1b.
 GN Name=gfralpha1b;
 OS Brachydanio rerio (Zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 ON NCBI_TaxID=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21135398; PubMed=11237470;
 RA Shepherd I.T., Beattie C.B., Raible D.W.,
 RT "Functional analysis of zebrafish GDNF.";
 RL Dev. Biol. 231:420-435(2001).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX PubMed=14660438;
 RA Shepherd I.T., Pietsch J., Elworthy S., Kelch R.N., Raible D.W.,
 RT "Roles for GFR(alpha1) receptors in zebrafish enteric nervous system
 RT development.";
 RL Development 131:241-249(2004).
 DR EMBL; AY436321; AK11261.2; -
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR003438; GDNF_receptor.
 DR Pfam; PF02351; GDNF, 1.
 DR PRINTS; PR01316; GDNFRECEPTOR.
 KM Receptor.

SEQUENCE 481 AA; 53639 MW; 478917653049CE23 CRC64;

Query Match 33.7%; Score 476.5; DB 2; Length 481;

Best Local Similarity 39.9%; Pred. No. 3.6e-32; Matches 93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;

QY 27 GSASSTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGMRGPGSCVRSRCHRALRRFF 86
 DB 152 GEAAFTKDNKCNLAAMAKCNLDNCKKRYSLIYSPCTSRVS--TTEVCNKKCKKALRQPF 209
 QY 87 ARGPALTLALLFCGC--EGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 143
 DB 210 DKVPPHSGYGMLEFCSPSGDHSACSRERRQTIYPACSYEDKE--KENCISLQASCKTNYI 267
 QY 144 CRPRLEFAFOASCAPAGSRDGCPEEGPRCLRAYAGLVGTVPNTYLDNVASAVAPWCGC 203
 DB 268 CSRSLADFLTNCGPEARSISGCLKENYADCLAYSGLIGVTMPNYLRAFGISVSFWCOC 327
 QY 204 EASGNRECEAFRKLFTNPCLDGAIOAFDS-----OPSVLQDDQWNPY 248
 DB 328 SNSGNKACDCDKEFTFTNNRCLRNALIOAFNGTIDVGWOPPPINSTADPY 380

RESULT 6

AAK11261 PRELIMINARY; PRT; 481 AA.

AC AAK11261; 02-MAR-2004 (TREMBlrel. 27, Created)
 DT 02-MAR-2004 (TREMBlrel. 27, Last sequence update)
 DT 02-MAR-2004 (TREMBlrel. 27, Last annotation update)
 DE GDNF family receptor alpha-1b.
 GN GPRALPHA1B
 OS Brachydanio rerio (zebrafish) (Danio rerio).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
 OC Cyprinidae; Danio.
 OC NCB1_Taxid=7955;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21135398; PubMed=11237470;
 RA Shepherd I.T., Beattie C.E., Raible D.W.;
 RT "Functional analysis of zebrafish GDNF.";
 RL Dev. Biol. 231:420-435 (2001).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX PubMed=14650438;
 RA Shepherd I.T., Pietsch J., Elworthy S., Kesh R.N., Raible D.W.;
 RT "Roles for GPR(alpha)1 receptors in zebrafish enteric nervous system development.";
 RL Development 131:241-249 (2004).
 DR EMBL; AY436321; AAK11261.2; -.
 KW Receptor.
 SQ SEQUENCE 481 AA; 53639 MW; 478917653049CE23 CRC64;

Query Match 33.7%; Score 476.5; DB 2; Length 481;
 Best Local Similarity 39.9%; Pred. No. 3.6e-32; Matches 93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;
 QY 27 GSASSTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGMRGPGSCVRSRCHRALRRFF 86
 DB 152 GEAAFTKDNKCNLAAMAKCNLDNCKKRYSLIYSPCTSRVS--TTEVCNKKCKKALRQPF 209
 QY 87 ARGPALTLALLFCGC--EGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 143
 DB 210 DKVPPHSGYGMLEFCSPSGDHSACSRERRQTIYPACSYEDKE--KENCISLQASCKTNYI 267
 QY 144 CRPRLEFAFOASCAPAGSRDGCPEEGPRCLRAYAGLVGTVPNTYLDNVASAVAPWCGC 203
 DB 268 CSRSLADFLTNCGPEARSISGCLKENYADCLAYSGLIGVTMPNYLRAFGISVSFWCOC 327
 QY 204 EASGNRECEAFRKLFTNPCLDGAIOAFDS-----OPSVLQDDQWNPY 248
 DB 328 SNSGNKACDCDKEFTFTNNRCLRNALIOAFNGTIDVGWOPPPINSTADPY 380

RESULT 7

Q922A2 PRELIMINARY; PRT; 330 AA.

ID Q922A2; 01-MAY-1999 (TREMBlrel. 10, Created)
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
 DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
 DE Glial cell line derived neurotrophic factor family receptor alpha 2c.
 GN Name=Gfra2;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCB1_Taxid=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wong Y.W., Too H.P.;
 RT "Identification of mammalian Gfra-2 splice isoforms.";
 RL Neuroreport 9:0-0 (1998).
 DR EMBL; AF079108; AAC82465.1; -.
 DR MGD; MGI:1195462; Gfra2.
 DR GO; GO:0004872; F:receptor activity; IEA.
 DR InterPro; IPR003438; GDNF_receptor.
 DR InterPro; IPR003504; GDNF_receptor2.
 DR Pfam; PF02351; GDNF_1.
 DR PRINTS; PRO1318; GDNFRALPHA2.
 DR PRINTS; PRO1316; GDNFRECEPTOR.
 KW Receptor.
 SQ SEQUENCE 330 AA; 36506 MW; ADA14BF4C277594 CRC64;

Query Match

Best Local Similarity 42.5%; Pred. No. 7.3e-32; Matches 91; Conservative 31; Mismatches 86; Indels 6; Gaps 3;

QY 22 LCGQRGSASTEGNRCVAAEACTADEOCQOLRSEVYVACLRAGMRGPGSCVRSRCHRA 81
 DB 13 LGTGADPVVASNSHCLDAKACNLDNCKKRSYSISCNBEIS--PTERCNRRCHKA 70
 QY 82 LRFPARGPALTLALLFCGCCEGPACARRRQTFAPACAFSGPOLAPPSCLKPLDRCSRR 141
 DB 71 LRQFPDRVSEYTYRNLFCSCODQACARRRQTIYPSCEYEDKE--KPNCLDRSLRCRD 128
 QY 142 RRCPRLEFAFOASCAPAGSRDGCPEEGPRCLRAYAGLVGTVPNTYLDN--VSARVAP 199
 DB 129 HICRSRLAPFHANCRASVYRTISCPADNYQACISYAGMIGPDMPTNYVDSNPTGIVASP 188
 QY 200 WGCCEASGNRECEAFRKLFTNPCLDGAIOAF 233
 DB 189 WCNCRGSGMBEBCERFLDFTENPCLRNALIOAF 222

RESULT 8

Q922A3 PRELIMINARY; PRT; 358 AA.

ID Q922A3; 01-MAY-1999 (TREMBlrel. 10, Created)
 DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
 DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
 DE Glial cell line derived neurotrophic factor family receptor alpha 2b.
 GN Name=Gfra2;
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCB1_Taxid=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA Wong Y.W., Too H.P.;
 RT "Identification of mammalian Gfra-2 splice isoforms.";
 RL Neuroreport 9:0-0 (1998).
 DR EMBL; AF079107; AAC82464.1; -.

Db 329 GNMEECEKFLRDPFTENPCLRNALQAF 355

RESULT 11

ID GFR2_MOUSE STANDARD; PRT; 463 AA.

AC 008432;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE GDNF family receptor alpha 2 precursor (GFR-alpha 2) (Neurturin receptor alpha) (NTRN-alpha) (TGF-beta related neurotrophic factor receptor 2) (GDNF receptor beta) (GDNFR-beta).

GN Name=Gfr2; Synonyms=gdnfrb, Trnr2;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RP [1]

RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).

RX MEDLINE=97325791; PubMed=9182803;

RA Balon R.H., Tansey M.G., Golden J.P., Creedon D.J., Heuckeroth R.O., Reck C.L., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr., Milbrandt J.;

RA "Trnr2, a novel receptor that mediates neurturin and GDNF signaling through Ret.";

RT Neuron 18:793-802(1997).

CC -1- FUNCTION: Receptor for neurturin. Mediates the NRTN-induced autophosphorylation and activation of the RET tyrosine kinase receptor.

CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).

CC -1- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=2;

CC Name=1; Synonyms=Long;

CC IsoId=O08842-1; Sequence=Displayed;

CC Name=2; Synonyms=Short;

CC IsoId=O08842-2; Sequence=VSP_001662;

CC -1- TISSUE SPECIFICITY: Neurons of the superior cervical and dorsal root ganglia, and adult brain and testis. Low level in the spleen and in the adrenal gland.

CC -1- SIMILARITY: Belongs to the GDNFR family.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - CC the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.1sb-sib.ch/announce/> or send an email to license@1sb-sib.ch).

CC -----

DR EMBL; AF002701; AAC53548.1; -

DR MGD; MGI:1195462; Gfr2.

DR InterPro: IPR003438; GDNF_receptor.

DR Pfam: PF02351; GDNF; 1

DR PRINTS; PR01316; GDNFRECEPTOR.

DR KMW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.

KW SIGNAL

FT CHAIN 1 21 Potential.

FT PROPEP 22 443 GDNF family receptor alpha 2.

FT CARBOHYD 444 463 Removed in mature form (Potential).

FT CARBOHYD 357 357 N-linked (GlcNAc...) (Potential).

FT CARBOHYD 413 413 N-linked (GlcNAc...) (Potential).

FT LIPID 443 443 GPI-anchor amidated serine (Potential).

FT VARSPLIC 14 146 Missing (in isoform 2).

FT VARSPLIC 14 146 Missing (in isoform 2).

SO SEQUENCE 463 AA; 51598 MW; 4FB495F858C61F78 CRC64;

Query Match 32.9%; Score 465; DB 1; Length 463;

Best Local Similarity 42.9%; Pred. No. 3.3e-31;

Matches 88; Conservative 32; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNRCVNAEAECTADEOCQQLRSEYVAOCLLRACRGSGCVSRRCRRALRRFPARCP 90

DB 155 SAKSNHCCLDAAKACNINDNCKLRSSYSISICNNEIS--PTERCNRRCKHKLQFPDRVP 212

QY 91 PALTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPSPCLKPLDRCCSRRCRPLFA 150

DB 213 SEYTYMLFCSCODQCAERRRQTIIPSCSYBKE--KENCULRSLCRTLHLCRSRLAD 270

QY 151 FOASCAPAPSGRDCEEGPRCLRAYAGLVGTVPNTLND--VSARVAPWCCEASGN 208

DB 271 FHANCRASRTITSCADANVQACLAGSYAGWIGFDMTPNYVDSNPTGIIVSPMNCNGSGN 330

QY 209 RRECGAPRKLFPNRPCLDGLQAF 233

DB 331 MESECEKFLRDPFTENPCLRNALQAF 355

RESULT 12

ID Q920Y3 PRELIMINARY; PRT; 463 AA.

AC Q920Y3;

DT 01-DEC-2001 (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

DE Glial cell line derived neurotrophic factor family receptor alpha 2.

GN Name=Gfr2;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RP [1]

RP SEQUENCE FROM N.A.

RP STRAIN=C57BL;

RX MEDLINE=22712886; PubMed=12829325;

RA Too H.P.;

RT "Real time PCR quantification of GFRalpha-2 alternatively spliced isoforms in murine brain and peripheral tissues.";

RT Brain Res. Mol. Brain Res. 114:146-153(2003).

RN [2]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL;

RA Wong Y.W., Too H.P.;

RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.

DR EMBL; AF398416; AAK97483.1; -

DR EMBL; AF398411; AAK97483.1; JOINED.

DR EMBL; AF398412; AAK97483.1; JOINED.

DR EMBL; AF398414; AAK97483.1; JOINED.

DR EMBL; AF398415; AAK97483.1; JOINED.

DR EMBL; AF398413; AAK97483.1; JOINED.

DR GO; GO:0004872; F:receptor activity; IEA.

DR InterPro: IPR003438; GDNF_receptor.

DR InterPro: IPR003504; GDNF_receptor2.

DR Pfam: PF02351; GDNF; 1.

DR PRINTS; PR01316; GDNFRECEPTOR.

DR KMW Receptor.

SO SEQUENCE 463 AA; 51582 MW; 42FA1BF5975E2C CRC64;

Query Match 32.9%; Score 465; DB 2; Length 463;

Best Local Similarity 42.9%; Pred. No. 3.3e-31;

Matches 88; Conservative 32; Mismatches 79; Indels 6; Gaps 3;

QY 31 STEGNRCVNAEAECTADEOCQQLRSEYVAOCLLRACRGSGCVSRRCRRALRRFPARCP 90

DB 155 SAKSNHCCLDAAKACNINDNCKLRSSYSISICNNEIS--PTERCNRRCKHKLQFPDRVP 212

QY 91 PALTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPSPCLKPLDRCCSRRCRPLFA 150

DB 213 SEYTYMLFCSCODQCAERRRQTIIPSCSYBKE--KENCULRSLCRTLHLCRSRLAD 270

QY 151 FOASCAPAPSGRDCEEGPRCLRAYAGLVGTVPNTLND--VSARVAPWCCEASGN 208

DB 271 FHANCRASRTITSCADANVQACLAGSYAGWIGFDMTPNYVDSNPTGIIVSPMNCNGSGN 330

QY 209 RRECGAPRKLFPNRPCLDGLQAF 233

DB 331 MESECEKFLRDPFTENPCLRNALQAF 355

Db 271 FHANCRASTYITISCPADNYACAGCGTAGMIGPMTNTYVDSNPTGTIVSPWQNCRCGSGN 330
 QY 209 RRECEAFRLKLTFRNPLCLDGAIOAF 233
 Db 331 MEECEKFLKDFTEFNPLCLRNAIOAF 355

RESULT 13
 GFR1_HUMAN STANDARD; PRT; 465 AA.
 ID GFR1_HUMAN STANDARD; PRT; 465 AA.
 AC P56159; O15507; O43912;
 DT 01-NOV-1997 (Rel. 35, Created)
 DT 28-FEB-2003 (Rel. 41, Last sequence update)
 DT 05-JUL-2004 (Rel. 44, Last annotation update)
 DE GDNF family receptor alpha 1 precursor (GFR-alpha 1) (GDNF receptor alpha) (GDNFR-alpha) (TGF-beta related neurotrophic factor receptor 1) (RET ligand 1).
 DE Name=GFR1; Synonyms=GDNFRA, TRNR1, RETL1;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 NC NCBI_TaxID=9606;
 RX [1]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Substantia nigra;
 RX MEDLINE=96270513; PubMed=8674117;
 RA Jing S., Wen D., Yu Y., Holst P.L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J.-C., Hu S., Altrock B.W., Fox G.M., Hu Z., Cupples R., Louis J.-C., Hu S., Altrock B.W., "GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.", Cell 85:1113-1124(1996).
 RL [2]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Kidney;
 RX MEDLINE=9732356; PubMed=9177201;
 RA Sandoz M., Hession C.A., Worley D.S., Carmillo P., Ehrenfels C., Walus L., Robinson S., Jaworski G., Wei H., Tizard R., Whitty A., Pepinsky R.B., Cate R.L., "Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins.", Proc. Natl. Acad. Sci. U.S.A. 94:6238-6243(1997).
 RL [3]
 RP SEQUENCE FROM N.A. (ISOFORM 1), AND VARIANTS ASN-85 AND ALA-366.
 RX MEDLINE=98207251; PubMed=9545641; DOI=10.1006/geno.1997.5191.
 RA Angrist M., Jing S., Bolk S., Bentley K., Mallsamy S., Halushka M., Fox G.M., Chakravarti A., "Human GFR1: cloning, mapping, genomic structure, and evaluation as a candidate gene for Hirschsprung disease susceptibility.", Genomics 48:354-362(1998).
 RL [4]
 RP SEQUENCE FROM N.A. (ISOFORM 1).
 RC TISSUE=Thyroid carcinoma;
 RX MEDLINE=98260874; PubMed=9600247;
 RA Shefelbine S.E., Khorana S., Schultz P.N., Huang E., Thobe N., Hu Z.J., Fox G.M., Jing S., Cote G.J., Gargel R.F., "Mutational analysis of the GDNF/RET-GDNFR-alpha signaling complex in a kindred with vesicoureteral reflux.", Hum. Genet. 102:474-478(1998).
 RL [5]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Substantia nigra;
 RA Hishiki T., Kondoh K., Ichimiya S., Nimura Y., Seki N., Ozaki T., Sakiyama S., Takahashi H., Ohnuma N., Tanabe M., Fujimura S., Nakagawa A., "GDNF-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-ret and GDNFR-alpha.", Submitted (Oct-1997) to the EMBL/GenBank/DBJ databases.
 RL [6]
 RP SEQUENCE FROM N.A. (ISOFORM 2).
 RC TISSUE=Eye;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Pelngold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Datchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares W.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Uebli T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loggellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulik S.W.,
 RA Villalón D.K., Mizny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
 RA Fahy J., Helton E., Kerteman M., Madan A., Rodriguez S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RA "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.",
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [7]
 RP SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
 RX PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
 RA Hillman R.T., Green R.E., Brenner S.E.,
 RT "An unappreciated role for RNA surveillance.",
 RL Genome Biol. 5:RESEARCH008.1-RESEARCH008.16(2004).
 RN [8]
 RP VARIANTS ALA-366 AND ARG-371.
 RX PubMed=1456559; DOI=10.1007/s00439-003-1036-z;
 RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
 RA Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
 RA Nakamura T., Hayasaka K.,
 RT "Molecular analysis of congenital central hypoventilation syndrome.",
 RL Hum. Genet. 114:22-26(2003).
 CC -1- FUNCTION: Receptor for GDNF. Mediates the GDNF-induced
 CC autophosphorylation and activation of the RET receptor (By
 CC similarity).
 CC -1- SUBUNIT: 2 molecules of GDNFR-alpha are thought to form a complex
 CC with the disulfide-linked GDNF dimer and with 2 molecules of RET
 CC (By similarity).
 CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By
 CC similarity).
 CC -1- ALTERNATIVE PRODUCTS:
 CC Name=1;
 CC IsoId=P56159-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=P56159-2; Sequence=VSP 001660;
 CC Note=May be produced at very low levels due to a premature stop
 CC codon in the mRNA, leading to nonsense-mediated mRNA decay;
 CC -1- SIMILARITY: Belongs to the GDNFR family.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC -----
 CC EMBL; U7144; AAC51646.1; -;
 CC EMBL; AF038420; AAC39693.1; -;
 CC EMBL; AF038421; AAC39693.1; JOINED.
 CC EMBL; AF038412; AAC39693.1; JOINED.
 CC EMBL; AF038413; AAC39693.1; JOINED.
 CC EMBL; AF038414; AAC39693.1; JOINED.
 CC EMBL; AF038415; AAC39693.1; JOINED.
 CC EMBL; AF038416; AAC39693.1; JOINED.
 CC EMBL; AF038417; AAC39693.1; JOINED.
 CC EMBL; AF038418; AAC39693.1; JOINED.
 CC EMBL; AF038419; AAC39693.1; JOINED.
 CC EMBL; AF038421; AAC39692.1; -;
 CC EMBL; AF042080; AAB97371.1; -;


```

DR EMBL; AF058999; AAC14431.1; -.
DR EMBL; AF058990; AAC14431.1; JOINED.
DR EMBL; AF058991; AAC14431.1; JOINED.
DR EMBL; AF058992; AAC14431.1; JOINED.
DR EMBL; AF058993; AAC14431.1; JOINED.
DR EMBL; AF058994; AAC14431.1; JOINED.
DR EMBL; AF058995; AAC14431.1; JOINED.
DR EMBL; AF058996; AAC14431.1; JOINED.
DR EMBL; AF058997; AAC14431.1; JOINED.
DR EMBL; AF058998; AAC14431.1; JOINED.
DR EMBL; AF058999; AAC14431.1; JOINED.
DR EMBL; U95847; AAB7181.1; -.
DR EMBL; BC014962; AAH14962.1; -.
DR GeneW; HGNC:4243; GFRAL.
DR MIM; 601496; -.
DR GO; GO:0019898; C.electrinic to membrane; NAS.
DR GO; GO:0004872; F:receptor activity; NAS.
DR GO; GO:0007166; P:cell surface receptor linked signal transdu. .; NAS.
DR InterPro; IPR003438; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;
KW Polymorphism; Receptor; Signal.
FT SIGNAL 1 24
FT CHAIN 25 429 GDNF family receptor alpha 1.
FT PROPEP 430 465 Removed in mature form (Potential).
FT DOMAIN 362 369 Poly-Thr.
FT CARBOHYD 359 369 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 347 347 N-linked (GlcNAc. .) (Potential).
FT CARBOHYD 406 406 N-linked (GlcNAc. .) (Potential).
FT LIPID 429 429 GPI-anchor amidated serine (Potential).
FT VARSPLIC 140 144 Missing (in isoform 2).
FT VARIANT 85 85 /FTId=VSP_001660.
FT VARIANT 85 85 Y -> N (in dDSNP:8192662).
FT VARIANT 366 366 /FTId=VAR_012488.
FT VARIANT 366 366 T -> A (in dDSNP:2072276).
FT VARIANT 371 371 /FTId=VAR_012489.
FT VARIANT 371 371 L -> R (may be involved in congenital
FT VARIANT 371 371 central hypoventilation syndrome).
FT CONFLICT 245 245 /FTId=VAR_018261.
FT CONFLICT 358 358 Missing (in Ref. 1).
FT SEQUENCE 465 AA; 51455 MW; 91A550D06A677BD CRC64;
SQ
Query Match
Best Local Similarity 41.9%; Score 465; DB 1; Length 465;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;
QY 33 EGNRCVEAAEACTADECCOQLRSEVVAOCLGRAGMRGPGSCVSRRCRRALRFPFARPPA 92
Db 150 KGNNCIDAAKAKCNLDICCKIKRSAYITPCTTSV---SNDVCNRKCKHAKLRQFFDKVPAK 206
QY 93 LTHALLFCGCEGPACERRRQTFAPACAFSGPQLAPSPCLKPLDRCSRRCPRLFAFO 152
Db 207 HSYGMLFSCCRDIACERRRQTIIVPCSYE--ERKPNCLNLDSCKTNYICGSRADLF 264
QY 153 AACCAPPGSRDGPREGGPRCLRAYGLVGTVTYVLDNVAARVAPWCCGCEASGNRRRE 212
Db 265 TNCQPSRSRVSSGLCKENYVADCLAYVGLGTWTPTVYIDSSISLVAIPWCDSCNSGNDLEE 324
QY 213 CEAFRLFTFRNPCLDGAIOAFDSSQPSVQDDQNP 247
Db 325 CLKFLNFQDNTCLKNAIOAFNGSDVTV---MQP 356
RESULT 14
ID 0725C2 PRELIMINARY; PRT; 331 AA.
AC 0725C2;
DT 01-OCT-2003 (TEMBLrel. 25, Created)
DT 01-OCT-2003 (TEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TEMBLrel. 26, Last annotation update)
DE Glial cell line-derived neurotrophic factor family receptor
alpha2c.

```

```

OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Young L.F., Too H.P.;
RU Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY326396; AAB88378.1; -.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR KW Receptor.
SQ SEQUENCE 331 AA; 36470 MW; 10ECEA5492E2333C CRC64;
Query Match
Best Local Similarity 32.8%; Score 464; DB 2; Length 331;
Matches 92; Conservative 38; Mismatches 102; Indels 6; Gaps 3;
QY 22 LGCQGSASTEGNRCVEAAEACTADECCOQLRSEVVAOCLGRAGMRGPGSCVSRRCRR 81
Db 13 LGTGADPVVSAKSNHCLDAKACNLDNCKKURSSYISICNBEIS--PTERCNRKCHXA 70
QY 82 LRFPARGPALTHALLFCGCEGPACERRRQTFAPACAFSGPQLAPSPCLKPLDRCSRS 141
Db 71 LRQFFRVPSYETTRMLFSCQDQACERRRQTIIVPCSYEDKE--KPNCLDRGVCRD 128
QY 142 RRCRPLFAFOASCAPAPSGRDGPREGGPRCLRAYGLVGTVTYVLDN--VSARVAP 199
Db 129 HLCRSRLADPFIANCRASTYQTVVSCPDNYQACLGSGVAGMIGPMTNYYDSSPTGIVS 188
QY 200 WCCGCEASGNRRRECEAFRLFTFRNPCLDGAIOAFDSSQPSVQDDQNPYQNAQAYE 257
Db 189 WCCSGSGNMBEBCERFLDFTENPCLRNAIOAFNGSDTVVNSPKGPSFOATQAPRVE 246
RESULT 15
ID 035252 PRELIMINARY; PRT; 463 AA.
AC 035252;
DT 01-JAN-1998 (TEMBLrel. 05, Created)
DT 01-JAN-1998 (TEMBLrel. 05, Last sequence update)
DT 01-JUN-2003 (TEMBLrel. 24, Last annotation update)
DE GDNF receptor beta.
GN Name=Gtrial; Synonyms=GDNFR-beta;
OC Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=98252741; PubMed=9592044;
RA Dey B.K., Wong Y.W., Too H.P.;
RT "Cloning of a novel murine isoform of the glial cell line-derived
RT neurotrophic factor receptor."
RT Neuroreport 9:37-42(1998).
DR EMBL; AF015172; AAB86600.1; -.
DR MGD; MG1:1100842; Gfral.
DR GO; GO:0004872; F:receptor activity; IEA.
DR InterPro; IPR003438; GDNF_receptor.
DR InterPro; IPR003503; GDNF_receptor.
DR Pfam; PF02351; GDNF; 1.
DR PRINTS; PRO1317; GDNFRALPHA1.
DR PRINTS; PRO1316; GDNFRECEPTOR.
DR KW Receptor.
SQ SEQUENCE 463 AA; 51134 MW; EAF2A1522622C037 CRC64;
Query Match
Best Local Similarity 32.8%; Score 464; DB 2; Length 463;
Matches 89; Conservative 32; Mismatches 87; Indels 8; Gaps 3;
QY 32 TEGNRCVEAAEACTADECCOQLRSEVVAOCLGRAGMRGPGSCVSRRCRRALRFPARGP 91

```

[illegible]

Search completed: January 26, 2005, 13:15:40
Job time : 193 secs


```

;
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-487-685-6
Query Match      33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGCVRSRCRRLRFFAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFFDR 210
QY 89 GPPALTHALLFCGCGGPACAEARRROTFAFAPACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACAEARRROTILPSCSYEDE--KPNCLDRSLCRTDHLCRSL 268
QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPYNYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCGRASYRTITSCPADNYQACLSGYAGMIGFDMTPNYVDSNPTGIIVSPWNCGRGS 328
QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 5
US-08-802-805D-6
; Sequence 6, Application US/0802805D
; Patent No. 6372453
; GENERAL INFORMATION:
; APPLICANT: Robert D. Klein
; TITLE OF INVENTION: Neurturin Receptor
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/802,805D
; FILING DATE: 18-Feb-1997
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, PhD., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P1086
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 464 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-08-802-805D-6

Query Match      33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGCVRSRCRRLRFFAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFFDR 210
QY 89 GPPALTHALLFCGCGGPACAEARRROTFAFAPACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACAEARRROTILPSCSYEDE--KPNCLDRSLCRTDHLCRSL 268
QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPYNYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCGRASYRTITSCPADNYQACLSGYAGMIGFDMTPNYVDSNPTGIIVSPWNCGRGS 328
QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

```

```

DB 211 VSESYTYRMLFSCGQOQACAEARRROTILPSCSYEDE--KPNCLDRSLCRTDHLCRSL 268
QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPYNYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCGRASYRTITSCPADNYQACLSGYAGMIGFDMTPNYVDSNPTGIIVSPWNCGRGS 328
QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 6
US-08-861-990-2
; Sequence 2, Application US/08861990
; Patent No. 6636259
; GENERAL INFORMATION:
; APPLICANT: Ibanez, Carlos F.
; APPLICANT: Arumae, Umas
; APPLICANT: Sariola, Hannu
; APPLICANT: Suanto, Petro
; APPLICANT: Tuppi, Miles
; APPLICANT: Saarna, Mart
; TITLE OF INVENTION: Glial Cell Line-Derived Neurotrophic Factor Receptors
; FILE REFERENCE: CEPH0418
; CURRENT APPLICATION NUMBER: US/08/861,990
; PRIOR FILING DATE: 1997-05-22
; PRIOR APPLICATION NUMBER: 08/747,842
; PRIOR FILING DATE: 1996-11-13
; PRIOR APPLICATION NUMBER: 60/006,619
; PRIOR FILING DATE: 1995-11-13
; PRIOR APPLICATION NUMBER: 60/015,767
; PRIOR FILING DATE: 1996-04-16
; PRIOR APPLICATION NUMBER: 60/021,965
; PRIOR FILING DATE: 1996-06-27
; PRIOR APPLICATION NUMBER: 60/020,638
; PRIOR FILING DATE: 1996-06-27
; PRIOR APPLICATION NUMBER: 60/020,639
; PRIOR FILING DATE: 1996-06-27
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 2
; LENGTH: 464
; TYPE: PRT
; ORGANISM: Rattus sp.
US-08-861-990-2

Query Match      33.2%; Score 469; DB 4; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

QY 29 ASTEGNRCVEAAEACTADECCQQLRSEVVAOCLGAGRGSGCVRSRCRRLRFFAR 88
DB 153 AVSTSNHCLDAKACNLNDNCKLRSSYISICNREIS--PTERCNRKCHKALRQFFDR 210
QY 89 GPPALTHALLFCGCGGPACAEARRROTFAFAPACAFSGPOLAPSCCLKPDRCSRRRCRPL 148
DB 211 VSESYTYRMLFSCGQOQACAEARRROTILPSCSYEDE--KPNCLDRSLCRTDHLCRSL 268
QY 149 FAFQASCAPAPGSRDCCPEEGGPRCLRAYAGLVGTVPYNYLDN--VSARVAPWCGCEAS 206
DB 269 ADFHANCGRASYRTITSCPADNYQACLSGYAGMIGFDMTPNYVDSNPTGIIVSPWNCGRGS 328
QY 207 GNRRECEAFRLKFTFNPCLDGAIOAF 233
DB 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 7
US-09-388-316C-6
; Sequence 6, Application US/09388316C
; Patent No. 6777196
; GENERAL INFORMATION:
; APPLICANT: KLEIN, ROBERT D.

```


LENGTH: 664 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 18:
 US-09-487-685-18

Query Match 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

29 ASSTEGNRCVEAAEACTADEQCQQLRSEYVAQCLGRAGMRGPGSCVRSRCRRALRRFPAR 88
 153 AVSTKSNHCLDAKACNLNDNCKKLRSSYSISICNREIS--PTERCNRRKCHKALRQFPDR 210
 89 GPPALTHALLFCGCEGPACERRROTFAFACAFSGPOLAPPSCLKPLDRCERSRRCRPL 148
 211 VPSEYTYRMLFSCQDQACERRROTILPSCSYEDKE--KPNCLDRLSLCRTDHLCRSL 268
 149 FAFQASCAPAPGSRDCEGPGRCRLRAYAGLVGTVTPTYLDN--VSARVAPWCGCEAS 206
 269 ADFHANCRASTYRTITSCPADNYOACLGSYAGMIGFDMPTNYDSNPTGIIVSPWCMCRGS 328
 207 GNRRECEAFRLKLTFRNPLDGAIOAF 233
 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 10
 US-08-802-805D-18
 Sequence 18, Application US/08802805D
 Patent No. 6372453
 GENERAL INFORMATION:
 APPLICANT: Robert D. Klein
 TITLE OF INVENTION: Neurturin Receptor
 NUMBER OF SEQUENCES: 28
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Genentech, Inc.
 STREET: 1 DNA Way
 CITY: South San Francisco
 STATE: California
 COUNTRY: USA
 ZIP: 94080
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Winpatin (Genentech)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/802,805D
 FILING DATE: 18-Feb-1997
 CLASSIFICATION: 536
 ATTORNEY/AGENT INFORMATION:
 NAME: Torchia, PhD., Timothy E.
 REGISTRATION NUMBER: 36,700
 REFERENCE/DOCKET NUMBER: P1086
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650/225-8674
 TELEFAX: 650/952-9881
 INFORMATION FOR SEQ ID NO: 18:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 664 amino acids
 TYPE: Amino Acid
 TOPOLOGY: Linear
 US-08-802-805D-18

Query Match 33.2%; Score 469; DB 3; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;
 29 ASSTEGNRCVEAAEACTADEQCQQLRSEYVAQCLGRAGMRGPGSCVRSRCRRALRRFPAR 88
 153 AVSTKSNHCLDAKACNLNDNCKKLRSSYSISICNREIS--PTERCNRRKCHKALRQFPDR 210

89 GPPALTHALLFCGCEGPACERRROTFAFACAFSGPOLAPPSCLKPLDRCERSRRCRPL 148
 211 VPSEYTYRMLFSCQDQACERRROTILPSCSYEDKE--KPNCLDRLSLCRTDHLCRSL 268
 149 FAFQASCAPAPGSRDCEGPGRCRLRAYAGLVGTVTPTYLDN--VSARVAPWCGCEAS 206
 269 ADFHANCRASTYRTITSCPADNYOACLGSYAGMIGFDMPTNYDSNPTGIIVSPWCMCRGS 328
 207 GNRRECEAFRLKLTFRNPLDGAIOAF 233
 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 11
 US-09-388-316C-18
 Sequence 18, Application US/09388316C
 Patent No. 6777196
 GENERAL INFORMATION:
 APPLICANT: KLEIN, ROBERT D.
 APPLICANT: HYNES, MARY A.
 TITLE OF INVENTION: NEURTURIN RECEPTOR
 FILE REFERENCE: GENENT.45A2DV1
 CURRENT APPLICATION NUMBER: US/09/388,316C
 PRIOR FILING DATE: 1999-09-01
 PRIOR APPLICATION NUMBER: 09/024,665
 PRIOR FILING DATE: 1998-02-17
 PRIOR APPLICATION NUMBER: 60/063,258
 PRIOR FILING DATE: 1997-10-24
 PRIOR APPLICATION NUMBER: 60/049,818
 PRIOR FILING DATE: 1997-06-09
 PRIOR APPLICATION NUMBER: 60/038,839
 PRIOR FILING DATE: 1997-02-18
 NUMBER OF SEQ ID NOS: 30
 SOFTWARE: FaSeq for Windows Version 4.0
 SEQ ID NO 18
 LENGTH: 664
 TYPE: PRT
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: This sequence is a fusion protein comprising rat
 NTRalpha sequence and human Fc sequence.
 US-09-388-316C-18

Query Match 33.2%; Score 469; DB 4; Length 664;
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;
 29 ASSTEGNRCVEAAEACTADEQCQQLRSEYVAQCLGRAGMRGPGSCVRSRCRRALRRFPAR 88
 153 AVSTKSNHCLDAKACNLNDNCKKLRSSYSISICNREIS--PTERCNRRKCHKALRQFPDR 210
 89 GPPALTHALLFCGCEGPACERRROTFAFACAFSGPOLAPPSCLKPLDRCERSRRCRPL 148
 211 VPSEYTYRMLFSCQDQACERRROTILPSCSYEDKE--KPNCLDRLSLCRTDHLCRSL 268
 149 FAFQASCAPAPGSRDCEGPGRCRLRAYAGLVGTVTPTYLDN--VSARVAPWCGCEAS 206
 269 ADFHANCRASTYRTITSCPADNYOACLGSYAGMIGFDMPTNYDSNPTGIIVSPWCMCRGS 328
 207 GNRRECEAFRLKLTFRNPLDGAIOAF 233
 329 GNMEECEKFLRDFTEPNCLRNAIOAF 355

RESULT 12
 US-09-187-906-9
 Sequence 9, Application US/09187906
 Patent No. 6677135
 GENERAL INFORMATION:
 APPLICANT: BIOGEN, INC.
 TITLE OF INVENTION: Ret ligand (RetL) for Stimulating Neural
 and Renal Growth

```

/ / NUMBER OF SEQUENCES: 21
/ / CORRESPONDENCE ADDRESS:
/ / ADDRESSEE: Biogen, Inc.
/ / STREET: 14 Cambridge Center
/ / CITY: Cambridge
/ / STATE: MA
/ / COUNTRY: USA
/ / ZIP: 02142
/ / COMPUTER READABLE FORM:
/ / MEDIUM TYPE: Floppy disk
/ / COMPUTER: IBM PC compatible
/ / OPERATING SYSTEM: PC-DOS/MS-DOS
/ / SOFTWARE: Patent In Release #1.0, Version #1.30
/ / CURRENT APPLICATION DATA:
/ / APPLICATION NUMBER: US/09/187,906
/ / FILING DATE:
/ / CLASSIFICATION:
/ / PRIOR APPLICATION DATA:
/ / APPLICATION NUMBER: PCT/US97/07726
/ / FILING DATE: 07-MAY-97
/ / APPLICATION NUMBER: US 60/017,427
/ / FILING DATE: 08-MAY-96
/ / PRIOR APPLICATION DATA:
/ / APPLICATION NUMBER: US 60/019,300
/ / FILING DATE: 07-JUN-96
/ / PRIOR APPLICATION DATA:
/ / APPLICATION NUMBER: US 60/021,859
/ / FILING DATE: 16-JUL-96
/ / PRIOR APPLICATION DATA:
/ / APPLICATION NUMBER: US 60/043,533
/ / FILING DATE: 10-APR-97
/ / ATTORNEY/AGENT INFORMATION:
/ / NAME: Kaplan, Warren A.
/ / REGISTRATION NUMBER: 34,199
/ / REFERENCE/DOCKET NUMBER: A008 PCT CIP
/ / TELECOMMUNICATION INFORMATION:
/ / TELEPHONE: 617-679-2400
/ / TELEFAX: 617-679-2838
/ / INFORMATION FOR SEQ ID NO: 9:
/ / SEQUENCE CHARACTERISTICS:
/ / LENGTH: 346 amino acids
/ / TYPE: amino acid
/ / TOPOLOGY: linear
/ / MOLECULE TYPE: protein
/ / US-09-187-906-9

Query Match      32.9%; Score 465; DB 4; Length 346;
Best Local Similarity 41.9%; Pred. No. 3.1e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAEACTADBOCCQQLRSEYVAOCLGRAGMRPGSCVRSRCRRALRRFFARGPPA 92
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 31 KGNNCIDAAKACNDDICKYRSAYITPCTTSV--SNDVCNRRCKHAKLRQFDKVPK 87
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 93 LTHALLFCGCGEPACAEERRRQTFAPACAFSGPOLAPPSCLPLDRCSRRCRPRLFAFQ 152
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 88 HSYGMFLFCSCRDIACTEERRRQTIIVPCSYE--EREKENCINLQDSCKTNYICRSLADFF 145
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 153 ASCAPAPGSRDGCPEEGPRCLRAYAGLVGTVTPTNYLDNVSARVAPWCGEASGNREE 212
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 146 TNCQPSRSVSSCKENYADCLLAYSGLIGVTMTPTNYIDSSSLVAPWCDSCNSGNDLEE 205
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 213 CEAFRLKFTNRPCLDGAIOAFDSQPSVLQDQWNP 247
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 206 CLKFLNPFKDNVTKLNAIOAFGNSDVTV---WQP 237
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 13
US-08-802-805D-22
/ / Sequence 22, Application US/08802805D
/ / Patent No. 6372453
/ / GENERAL INFORMATION:
/ / APPLICANT: Robert D. Klein
```

```

/ / TITLE OF INVENTION: Neurturin Receptor
/ / NUMBER OF SEQUENCES: 28
/ / CORRESPONDENCE ADDRESS:
/ / ADDRESSEE: Genentech, Inc.
/ / STREET: 1 DNA Way
/ / CITY: South San Francisco
/ / STATE: California
/ / COUNTRY: USA
/ / ZIP: 94080
/ / COMPUTER READABLE FORM:
/ / MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
/ / COMPUTER: IBM PC compatible
/ / OPERATING SYSTEM: PC-DOS/MS-DOS
/ / SOFTWARE: WinPatIn (genentech)
/ / CURRENT APPLICATION DATA:
/ / APPLICATION NUMBER: US/08/802,805D
/ / FILING DATE: 18-Feb-1997
/ / CLASSIFICATION: 536
/ / ATTORNEY/AGENT INFORMATION:
/ / NAME: Torchia, PhD., Timothy E.
/ / REGISTRATION NUMBER: 36,700
/ / REFERENCE/DOCKET NUMBER: PI086
/ / TELECOMMUNICATION INFORMATION:
/ / TELEPHONE: 650/225-8674
/ / TELEFAX: 650/952-9881
/ / INFORMATION FOR SEQ ID NO: 22:
/ / SEQUENCE CHARACTERISTICS:
/ / LENGTH: 460 amino acids
/ / TYPE: Amino acid
/ / TOPOLOGY: Linear
/ / US-08-802-805D-22

Query Match      32.9%; Score 465; DB 3; Length 460;
Best Local Similarity 41.9%; Pred. No. 4.3e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAEACTADBOCCQQLRSEYVAOCLGRAGMRPGSCVRSRCRRALRRFFARGPPA 92
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 145 KGNNCIDAAKACNDDICKYRSAYITPCTTSV--SNDVCNRRCKHAKLRQFDKVPK 201
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 93 LTHALLFCGCGEPACAEERRRQTFAPACAFSGPOLAPPSCLPLDRCSRRCRPRLFAFQ 152
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 202 HSYGMFLFCSCRDIACTEERRRQTIIVPCSYE--EREKENCINLQDSCKTNYICRSLADFF 259
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 153 ASCAPAPGSRDGCPEEGPRCLRAYAGLVGTVTPTNYLDNVSARVAPWCGEASGNREE 212
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 260 TNCQPSRSVSSCKENYADCLLAYSGLIGVTMTPTNYIDSSSLVAPWCDSCNSGNDLEE 319
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 213 CEAFRLKFTNRPCLDGAIOAFDSQPSVLQDQWNP 247
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 320 CLKFLNPFKDNVTKLNAIOAFGNSDVTV---WQP 351
/ / : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
```

```

RESULT 14
US-09-187-906-11
/ / Sequence 11, Application US/09187906
/ / Patent No. 6677135
/ / GENERAL INFORMATION:
/ / APPLICANT: BIOGEN, INC.
/ / TITLE OF INVENTION: Ret Ligand (RetL) for Stimulating Neural
/ / TITLE OF INVENTION: and Renal Growth
/ / NUMBER OF SEQUENCES: 21
/ / CORRESPONDENCE ADDRESS:
/ / ADDRESSEE: Biogen, Inc.
/ / STREET: 14 Cambridge Center
/ / CITY: Cambridge
/ / STATE: MA
/ / COUNTRY: USA
/ / ZIP: 02142
/ / COMPUTER READABLE FORM:
/ / MEDIUM TYPE: Floppy disk
/ / COMPUTER: IBM PC compatible
/ / OPERATING SYSTEM: PC-DOS/MS-DOS
```



```

      : SEQ ID NO 10
      : LENGTH: 463
      : TYPE: PROT
      : ORGANISM: HUMAN
      : FEATURE:
      : NAME/KEY: misc_feature
      : LOCATION: (5)..(5)
      : OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
      : NAME/KEY: misc_feature
      : LOCATION: (1)..(537)
      : OTHER INFORMATION: No. 6455277e= "1 to 537 is -235 to 301 of Figure 5 2lacon"
      : NAME/KEY: misc_feature
      : LOCATION: (550)..(550)
      : OTHER INFORMATION: N in position 550 indicates any nucleic acid
      US-08-837-199A-10

Query Match          32.9%; Score 465; DB 4; Length 463;
Best Local Similarity 41.9%; Pred. No. 4,3e-35;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

Oy   EGNRCVEAAEACTADBOCCOLRSEKTVVACLGAGRWGPGSCVYRSRCRALRRFPFAPGA 92
      ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db   KKNNCCLDAKKACNDDIDCKYRSAYITCTTSV---SNDVCNRKRCHALRLRFDFKVPAK 206
      LTHALLFCGCGEPGCAERROTTFADACA FSGEQ LAPPSCLKPLDRCERSRCPRIIFAQ 152
Oy   HSYGMLFCSCNDIAC TTERRTIVPVCSYE--EREKPNCINLQDSCKTNYICRSRLADPF 264
      ASCA PAPCSRGCPEEGPRCLRAAGVGVTVTNTNYLDNVSARVA VPMCGCAGGRBE 212
Db   TNCDBESRSVSSCLKENYADCLLASGLIGVTMTNYYIDSSLVA PWCDCNSGNDLEB 324
      CEAFRKLFTRNPCLDGAIOAFDSSQPSVLODPMP 247

```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using bw model

Run on: January 26, 2005, 12:53:26 ; Search time 158 Seconds
(without alignments)
585.773 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413
Sequence: 1 MSGAVLRVLRNRPQAVLW.....SVLDQDMRYQNAQAKVRA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 35872929 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : A_Geneseq_23Sep04:*

1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|--------|-------------|--------|----------|--------------------|
| 1 | 1413 | 100.0 | 258 | AA61637 | Aab61637 Rat GPR1 |
| 2 | 1386 | 98.1 | 273 | AA61636 | Aab61636 Rat GPR1 |
| 3 | 1078 | 76.3 | 277 | AA62103 | Aab62103 Mouse Ret |
| 4 | 1078 | 76.3 | 476 | AA62107 | Aab62107 Murine Re |
| 5 | 1075.5 | 76.1 | 260 | AA62106 | Aab62106 Mouse Ret |
| 6 | 1075.5 | 76.1 | 260 | AB809214 | Abb09214 Mouse GPI |
| 7 | 1075.5 | 76.1 | 293 | AB809215 | Abb09215 Mouse put |
| 8 | 1028.5 | 72.8 | 264 | AA62104 | Aab62104 Mouse Ret |
| 9 | 927.7 | 65.6 | 340 | AA42771 | Aay42771 Murine gl |
| 10 | 920.5 | 65.1 | 269 | AB809217 | Abb09217 Human GPI |
| 11 | 914.5 | 64.7 | 282 | AA62105 | Aab62105 Human Ret |
| 12 | 767.5 | 54.3 | 299 | AB809218 | Abb09218 Human put |
| 13 | 649.5 | 46.0 | 182 | AB809219 | Abb09219 Human put |
| 14 | 569.5 | 40.3 | 190 | AB809216 | Abb09216 Mouse Ret |
| 15 | 515 | 36.4 | 132 | AA805369 | Aae05369 Mouse Rec |
| 16 | 515 | 36.4 | 132 | AB872385 | Abb72385 Murine pr |
| 17 | 469 | 33.2 | 460 | AAW71602 | Aaw71602 Rat neur |
| 18 | 469 | 33.2 | 464 | AAW71602 | Aaw71602 Rat neur |
| 19 | 469 | 33.2 | 464 | AAW92289 | Aaw92289 Rat GDNF |
| 20 | 469 | 33.2 | 464 | AAW90122 | Aay90122 Rat neur |
| 21 | 469 | 33.2 | 464 | AB879036 | Abb79036 Rat neur |
| 22 | 469 | 33.2 | 464 | AB809630 | Abb09630 Amino aci |
| 23 | 469 | 33.2 | 464 | AAU79266 | Aau79266 Rat neur |
| 24 | 469 | 33.2 | 464 | ADD11657 | Add11657 Rat neur |
| 25 | 469 | 33.2 | 464 | AD854591 | Ad854591 Rat Prote |

| | | | | | | |
|----|-----|------|-----|---|----------|--------------------|
| 26 | 469 | 33.2 | 464 | 7 | AD863251 | Ad863251 Rat Prote |
| 27 | 469 | 33.2 | 664 | 2 | AAW71604 | Aaw71604 Rat neur |
| 28 | 469 | 33.2 | 664 | 3 | AAW80124 | Aay80124 Rat TNFR |
| 29 | 469 | 33.2 | 664 | 5 | AB879038 | Abb79038 Rat TNFR |
| 30 | 469 | 33.2 | 664 | 5 | AB809632 | Abb09632 Rat neur |
| 31 | 469 | 33.2 | 664 | 5 | AAU79268 | Aau79268 Rat TNFR |
| 32 | 469 | 33.2 | 664 | 7 | ADD11669 | Add11669 Rat TNFR |
| 33 | 469 | 33.2 | 951 | 3 | AAW15180 | Aay15180 gd-GPR1d |
| 34 | 467 | 33.1 | 330 | 2 | AAW81627 | Aaw81627 Mouse TGF |
| 35 | 465 | 32.9 | 346 | 2 | AAW37458 | Aaw37458 Human Ret |
| 36 | 465 | 32.9 | 346 | 8 | ADJ58701 | Adj58701 Human ret |
| 37 | 465 | 32.9 | 411 | 2 | AAW81625 | Aaw81625 Mouse met |
| 38 | 465 | 32.9 | 460 | 2 | AAW37459 | Aaw37459 Human Ret |
| 39 | 465 | 32.9 | 460 | 3 | AAW15175 | Aay15175 Human GPR |
| 40 | 465 | 32.9 | 460 | 6 | AB879180 | Abb79180 Tumour-ab |
| 41 | 465 | 32.9 | 460 | 8 | ADJ58703 | Adj58703 Human ret |
| 42 | 465 | 32.9 | 463 | 2 | AAW81624 | Aaw81624 Mouse TGF |
| 43 | 465 | 32.9 | 463 | 2 | AAW84167 | Aaw84167 GDNF-r1p |
| 44 | 465 | 32.9 | 463 | 2 | AAW84166 | Aaw84166 GDNF-r1p |
| 45 | 465 | 32.9 | 465 | 2 | AAW35333 | Aaw35333 Human gli |

ALIGNMENTS

RESULT 1
ID AAB61637 standard; protein; 258 AA.
XX
AC AAB61637;
XX

DT 06-APR-2001 (first entry)
XX

DE Rat GPRalpha-4 splice variant B.
XX

KM Rat; GPRalpha-4; carcinoma; familial hirschsprung disease; pain;
XX

KM Glial cell-line derived neurotrophic factor; neurodegenerative disease;
XX

KM GDNF family receptor alpha-4; Alzheimer's disease; Parkinson's disease;
XX

KW motor neuron disease; peripheral neuropathy; spinal cord injury;
XX

OS Rattus rattus.
XX

PN WO200102557-A1.
XX

PD 11-JAN-2001.
XX

PF 26-MAY-2000; 2000WO-EP004918.
XX

PR 29-JUN-1999; 99GB-00015200.
XX

PA (JANC) JANSSEN PHARM NV.
XX

PI Masure SLJ, Ctk M, Hoefnagel EW;
XX

DR WPI, 2001-138137/14.
XX

PT Glial cell-line derived neurotrophic factor family receptor alpha-4,
XX

PT useful for preparing medicaments for treating neurodegenerative diseases
XX

PT (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.
XX

PS Claim 14, Page 74-75; 82pp; English.
XX

The present sequence is rat Glial cell-line Derived Neurotrophic Factor (GDNF) family receptor alpha-4 (GPRalpha-4) splice variant B. GPRalpha-4 is useful in the preparation of a medicament for the treatment of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, motor neuron disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, carcinomas, and diseases associated with GPRalpha-4 receptor dysfunction and in alleviating pain. The rat GPRalpha-4 gene (see AAB61637) is localised on chromosome 3q36

SQ Sequence 258 AA;

Query Match 100.0%; Score 1413; DB 4; Length 258;
 Best Local Similarity 100.0%; Pred. No. 2.1e-123;
 Matches 258; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLSGAYLRVTLNERPGQAVLMSIGCGSGASSTEGNRCVFAAABACTADECCQQLRSEYVAQ 60
 DB 1 MLSGAYLRVTLNERPGQAVLMSIGCGSGASSTEGNRCVFAAABACTADECCQQLRSEYVAQ 60
 QY 61 CLGRAGMRPGSGCVSRRCRRALRRFFARGPALTHALLFCGCEGPACAEERRQTAPACA 120
 DB 61 CLGRAGMRPGSGCVSRRCRRALRRFFARGPALTHALLFCGCEGPACAEERRQTAPACA 120
 QY 121 FSGPOLAPSPCLKPLDRCSRRRCRPLFAFQASCAPAGSRDGCPEEGPRCLRAYAGL 180
 DB 121 FSGPOLAPSPCLKPLDRCSRRRCRPLFAFQASCAPAGSRDGCPEEGPRCLRAYAGL 180
 QY 181 VGTVTVPNYLDNVSAVAWPCGCEASGNRRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 DB 181 VGTVTVPNYLDNVSAVAWPCGCEASGNRRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 QY 241 LODQNPYQNAQAKEYEA 258
 DB 241 LODQNPYQNAQAKEYEA 258

RESULT 2

AAB61636 standard; protein; 273 AA.

AC AAB61636;
 DT 06-APR-2001 (first entry)
 XX

DE Rat GFRA1pha-4 splice variant A.

XX Rat; GFRA1pha-4; carcinoma; familial hirschsprung disease; pain;
 KW Glial cell-line derived neurotrophic factor; neurodegenerative disease;
 KM GDNF family receptor alpha-4; Alzheimer's disease; Parkinson's disease;
 KW motor neuron disease; peripheral neuropathy; spinal cord injury;
 KM chromosome 3q35.

OS Rattus rattus.

PN WO200102557-A1.

PD 11-JAN-2001.

PF 26-MAY-2000; 2000WO-EP004918.

PR 29-JUN-1999; 99GB-00015200.

PA (JANNC) JANSSEN PHARM NV.

PI Measure SLJ, Cik M, Hoefnagel EW;

DR WPI; 2001-138137/14.

DR N-PSDB; AAF31061, AAF31062.

PT Glial cell-line derived neurotrophic factor family receptor alpha-4,
 useful for preparing medicaments for treating neurodegenerative diseases
 (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.

PS Claim 14; Page 73-74; 82pp; English.

CC The present sequence is rat Glial cell-line Derived Neurotrophic Factor
 (GDNF) family receptor alpha-4 (GFRA1pha-4) splice variant A. GFRA1pha-4
 is useful in the preparation of a medicament for the treatment of
 CC neurodegenerative diseases, Alzheimer's disease, Parkinson's disease,
 CC motor neuron disease, peripheral neuropathy, spinal cord injury, familial
 CC hirschsprung disease, carcinomas, and diseases associated with GFRA1pha-4
 CC receptor dysfunction and in alleviating pain. The rat GFRA1pha-4 gene

CC (see AAF31061) is localised on chromosome 3q36

SQ Sequence 273 AA;

Query Match 98.1%; Score 1386; DB 4; Length 273;
 Best Local Similarity 100.0%; Pred. No. 7.5e-121;
 Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLSGAYLRVTLNERPGQAVLMSIGCGSGASSTEGNRCVFAAABACTADECCQQLRSEYVAQ 60
 DB 1 MLSGAYLRVTLNERPGQAVLMSIGCGSGASSTEGNRCVFAAABACTADECCQQLRSEYVAQ 60
 QY 61 CLGRAGMRPGSGCVSRRCRRALRRFFARGPALTHALLFCGCEGPACAEERRQTAPACA 120
 DB 61 CLGRAGMRPGSGCVSRRCRRALRRFFARGPALTHALLFCGCEGPACAEERRQTAPACA 120
 QY 121 FSGPOLAPSPCLKPLDRCSRRRCRPLFAFQASCAPAGSRDGCPEEGPRCLRAYAGL 180
 DB 121 FSGPOLAPSPCLKPLDRCSRRRCRPLFAFQASCAPAGSRDGCPEEGPRCLRAYAGL 180
 QY 181 VGTVTVPNYLDNVSAVAWPCGCEASGNRRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 DB 181 VGTVTVPNYLDNVSAVAWPCGCEASGNRRRECEAFRKLFTRNPCLDGAIQAFSSQPSV 240
 QY 241 LODQNPYQNAQAKEYEA 252
 DB 241 LODQNPYQNAQAKEYEA 252

RESULT 3

AAB62103 standard; protein; 277 AA.

AC AAB62103;
 DT 29-MAY-2001 (first entry)
 XX

DE Mouse RetL5 polypeptide.

XX Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KW vulnerability; nocotropic; anti-HIV; neuroprotective; antibacterial;
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.

OS Mus sp.

FH Location/Qualifiers

FT 1..21

FT /note= "signal peptide"

FT 22..277

FT /note= "mature protein"

FN WO2001016169-A2.

PD 08-MAR-2001.

PE 01-SEP-2000; 2000WO-US024111.

PR 01-SEP-1999; 99US-0152024P.

PA (BIOJ) BIOGEN INC.

PI ~~Wetley~~ D;

DR WPI; 2001-235091/24.

DR N-PSDB; AAF57270.

PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX Claim 13; Fig 3; 76pp; English.

XX Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KW vulnerability; neurotropic; anti-HIV; neuroprotective; antibacterial;
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 OS Mus sp.
 XX
 XX MO200116169-A2.
 XX
 XX 08-MAR-2001.
 XX
 XX 01-SEP-2000; 2000WO-US024111.
 XX
 XX 01-SEP-1999; 99US-0152024P.
 XX
 XX (BIO)) BIOGEN INC.
 XX
 XX Worley D;
 XX
 XX WPI; 2001-235091/24.
 XX N-PSDB; AAF57273.
 DR
 XX Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Disclosure; Fig 8; 76pp; English.
 XX
 XX The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumor
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events
 CC such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents an alternatively spliced mouse
 CC RetL5 polypeptide
 CC
 XX
 XX Sequence 260 AA;
 SQ
 Query Match 76.1%; Score 1075.5; DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;

QY 204 EASGNRECEAFRLFTRNPCLDGAIQAFDSQPSVLODQ 244
 DB 196 AASGNRRECEAFRLFTRNPCLDGAIQAFDSQPSVLODQ 226
 RESULT 6
 ABB09214
 ID ABB09214 standard; protein, 260 AA.
 XX
 XX ABB09214;
 AC
 XX 08-JUL-2002 (first entry)
 DT
 XX Mouse GPI-anchored isoform a1 protein SEQ ID NO:1.
 DE
 XX GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic;
 KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.
 XX
 OS Mus musculus.
 XX
 XX WO200162795-A1.
 XX
 XX 30-AUG-2001.
 XX
 XX 14-NOV-2000; 2000WO-FI00994.
 XX
 XX 21-FEB-2000; 2000FI-00000394.
 XX
 XX (LICE-) LICENTIA LTD.
 XX
 XX Atrakainen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
 PI Rossi U;
 XX
 DR WPI; 2001-596722/67.
 XX N-PSDB; ABL51669.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT preventing cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 1B5; 143pp; English.
 XX
 XX The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR) alpha4, or its fragments. GFRalpha4 sequences have cytosolic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC neoplasia, endocrine tumours, medullary thyroid carcinoma and
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRalpha 4 protein, designated GPI-anchored
 CC isoform a1, from the present invention
 CC
 XX
 XX Sequence 260 AA;
 SQ
 Query Match 76.1%; Score 1075.5; DB 4; Length 260;
 Best Local Similarity 89.6%; Pred. No. 6.5e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;

Db 16 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGGRPGGCVSRRCRRALR 75
 Qy 84 RFPARGPALTLTHALLFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCLEKPLDRCRSRR 143
 Db 76 RFPARGPALTLTHALLFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCLEKPLDRCRSRR 135
 Qy 144 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVPNTYLDNVASRVAPWCGC 203
 Db 136 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVPNTYLDNVASRVAPWCGC 195
 Qy 204 EASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 244
 Db 196 AASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 236
 RESULT 7
 ABB09215
 ID ABB09215 standard; protein; 293 AA.
 AC ABB09215;
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Mouse putative transmembrane isoform a2 protein SEQ ID NO:2.
 XX
 KM GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
 KM glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KM glial cell line derived neurotrophic factor; osteopathic; tumour;
 KM neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KM medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KM neuronal disorder; aberrant axonal sprouting.
 XX
 OS Mus musculus.
 XX
 PN WO200162795-A1.
 XX
 PD 30-AUG-2001.
 XX
 PF 14-NOV-2000; 2000WO-FI000994.
 XX
 PR 21-FEB-2000; 2000FI-0000394.
 XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Aitzkainen M, Saarma M, Poterbaev D, Lindahl M, Timmusk T;
 PI Rossi J;
 DR MPI: 2001-596722/67.
 DR N-PSDB; ABL51670.
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR)alpha4.
 PS Claim 9; Fig 19B; 143pp; English.
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recoding GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be are used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC neoplasia, endocrine tumours, medullary thyroid carcinoma and for
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the mouse GFRalpha 4 protein, designated putative

CC transmembrane isoform a2, from the present invention
 XX
 SQ Sequence 293 AA;
 Query Match 76.1%; Score 1075.5; DB 4; Length 293;
 Best Local Similarity 89.6%; Pred. No. 7.4e-92;
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;
 Qy 27 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGGRPGGCVSRRCRRALR 83
 Db 16 GSASFTDGNRCVDAABACTADDERCOQLRSEYVARCLGRAAPGGRPGGCVSRRCRRALR 75
 Qy 84 RFPARGPALTLTHALLFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCLEKPLDRCRSRR 143
 Db 76 RFPARGPALTLTHALLFCGCEGSPACARRRQTPAPACAFSGPOLAPPSCLEKPLDRCRSRR 135
 Qy 144 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVPNTYLDNVASRVAPWCGC 203
 Db 136 CRPRLLAFQASCAPAPGSRDGCPEEGGPRCLRAVAGLVGTVPNTYLDNVASRVAPWCGC 195
 Qy 204 EASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 244
 Db 196 AASGNRRECEAFRKLFTNPNCLDGAIOAFDSQSPSVLQDQ 236
 RESULT 8
 AAB62104
 ID AAB62104 standard; protein; 264 AA.
 AC AAB62104;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE Mouse RetL5 polypeptide.
 XX
 KM Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;
 KM vulnerable; noctropic; anti-HIV; neuroprotective; antibacterial;
 KM cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 XX
 OS Mus sp.
 XX
 FH Key location/Qualifiers
 FH Peptide 1..21
 FT /note= "signal peptide"
 FT Protein 22..264
 FT /note= "mature protein"
 PN WO200116163-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 01-SEP-2000; 2000WO-US024111.
 XX
 PR 01-SEP-1999; 99US-0152024P.
 XX
 PA (BIOJ) BIOGEN INC.
 XX
 PI Worley D;
 DR MPI: 2001-235091/24.
 DR N-PSDB; AAF57271.
 PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Claim 13; Fig 4; 76pp; English.
 CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their

antibodies are useful for stimulating growth of or limiting damage to, Ret expressing tissue in a subject, for suppressing growth of a tumour cell that expresses Ret, for modulating Ret signal transduction involving a cell expressing the Ret polypeptide. The Ret's polypeptides, fusion proteins containing Ret's and antibodies are useful for stimulating renal tissue growth and/or survival, supporting renal function and mimicking damage to renal tissue after various insults, particularly for treating acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury and trauma. The compounds are also useful for treating conditions such as neural degeneration where neural growth and regeneration are desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as motor neuron disease, demyelinating disease, bacterial diseases, viral diseases, and prion diseases including Creutzfeldt-Jakob disease. The compounds are also useful for treating disorders due to damage to neural tissue caused by neoplastic impingement, trauma or cerebrovascular events such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the mouse Ret's polypeptide predicted from D5W300 sequence by GENSCAN/GENE ALEX

Sequence 264 AA;

Query Match 72.8%; Score 1028.5; DB 4; Length 264;
Best Local Similarity 86.9%; Pred. No. 1.6e-87;
Matches 192; Conservative 7; Mismatches 13; Indels 9; Gaps 2;

27 GSASTEGNRCVEAEACTADDECOQLRSEVVAOCLGRA---GMRPGSCVRSRCRRALR 83
16 GSASTFDGRCVDAEAECTADDERCOQLRSEVVAARCLGRAAPGPGGCVRSRCRRALR 75
84 RPFAPGPPALTHALLFCGCGEGPACABRRROTAPACAFSPGOLAPSPCLAPLDERCERSR 143
76 RPFAPGPPALTHALLFCGCGEGSACABRRROTAPACAFSPGOLAPSPCLAPLDERCERSR 135
144 CRPLFAFOASCAPAPGSRDCEBEGGPRCLRAVAGLVGTWVTPNYLDNVSAARVAPWCGC 203
136 CR-----CASCAPAPGSRDRCPBEGGPRCLRAVAGLVGTWVTPNYLDNVSAARVAPWCGC 189
204 EASGNRECECFRKLFTFRNPCLDGAIOAFDSSQPSVLODQ 244
190 AASGNRRECEAFRLFTFRNPCLDGAIOAFDLSQPSVLODQ 230

RESULT 9
AAV42771
ID AAV42771 standard; protein; 340 AA.
XX
XX AAV42771;
AC
XX
XX
DT 05-JAN-2000 (first entry)
XX
XX
DE Murine glial derived neurotrophic factor receptor-alpha-X protein.
XX
XX Glial derived neurotrophic factor alpha-X; GFR-alpha-X; neural cell;
XX survival; function; nervous system; signalling; diagnosis; treatment;
XX neurological disorder; sensory disorder; Djerjine-Roussey syndrome;
XX contralateral anaesthesia; eating disorder; obesity; motor disorder;
XX Parkinson's disease; amyotrophic lateral sclerosis; ALS;
XX cognitive disorder; Alzheimer's disease.
XX
XX Mus sp.
OS
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 201
FT Misc-difference 217 /note= "Encoded by ANG"
FT Misc-difference 217 /note= "Encoded by ANN"
FT Misc-difference 340 /note= "Encoded by TCG"
XX
XX
XX W0950298-A1.

XX
PD 07-OCT-1999
XX
XX
PF 25-MAR-1999; 99WO-US006631.
XX
XX
PR 31-MAR-1998; 98US-0080070P.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX
PI Moore KJ;
XX
XX WPI: 1999-591276/50.
DR N-PEDB; AA228259.
XX
XX
PT A nucleic acid molecule that encodes GDNF Family Receptor alpha-X
PT protein, methods of isolation and antibodies - useful for the detection
PT of homologues and identification of binding compounds.
XX
XX
PS Claim 1; Fig 1; 100pp; English.

This sequence represents murine glial derived neurotrophic factor receptor-alpha-X (GFR-alpha-X) protein. GFR-alpha-X is a fourth member of the glial derived neurotrophic (GFR-alpha) family of receptors. The cDNA was identified in a positional cloning process in which the mouse mahogany locus was being sequenced to identify genes involved in obesity. The GFR-alpha-X protein binds to neurotrophic factors such as GDNF (glial cell line-derived neurotrophic factor) and/or NTN (neurturin), and mediates signalling within cells expressing the GFR-alpha-X protein. GFR-alpha-X, like the other three members of the GFR-alpha family (GFR-alpha-1, -2, and -3), transmits a signal to the interior of a cell by activation of the RRT protein tyrosine kinase signalling pathway. Neurotrophic factors promote survival and function of neural cells of both the central and peripheral nervous systems. Modulation of GFR-alpha-X activity can result in modulation of the neurotrophic factor-initiated cell function. Probes and/or primers derived from GFR-alpha-X cDNA, and antibodies against the protein are used to detect the presence of GFR-alpha-X nucleic acids or protein and can be used in the diagnosis and treatment of a variety of neurological disorders, including sensory disorders (e.g., Djerjine-Roussey syndrome, contralateral anaesthesia, and certain eating disorders), motor disorders (e.g., Parkinson's disease, amyotrophic lateral sclerosis), and cognitive disorders (e.g., Alzheimer's disease). In addition, compounds which bind to GFR-alpha-X may be used to modulate the activity of the protein

Sequence 340 AA;

Query Match 65.6%; Score 927; DB 2; Length 340;
Best Local Similarity 68.2%; Pred. No. 6.3e-78;
Matches 180; Conservative 10; Mismatches 28; Indels 46; Gaps 3;

27 GSASTEGNRCVEAEACTADDECOQLRSEVVAOCLGRA---GMRPGSCVRSRCRRALR 83
19 GSASTFDGRCVDAEAECTADDERCOQLRSEVVAARCLGRAAPGPGGCVRSRCRRALR 78
84 RPFAPGPPALTHALLFCGCGEGPACABRRROTAPACAFSPGOLAPSPCLAPLDERCERSR 143
76 RPFAPGPPALTHALLFCGCGEGSACABRRROTAPACAFSPGOLAPSPCLAPLDERCERSR 138
144 CRPLFAFOASCAPAPGSRDCEBEGGPRCLRAVAGLVGTWVTPNYLDNVSAARVAPWCGC 203
139 CRPLFAFOASCAPAPGSRDRCPBEGGPRCLRAVAGLVGTWVTPNYLDNVSAARVAPWCGC 198
204 EASGNRECECFRKLFTFRNPCLDGAIOAFDSSQPSVLODQ 244
199 AAXKRPARRMRSLPQALYXGTPAWVRGPGGPRGSRVSAOSKLPGLPVLTSHHWCGRW 258
224 ---PCLDGAIOAFDSSQPSVLODQ 244
259 TVTCTHGDGAIOAFDLSQPSVLODQ 282

RESULT 10
ABB09217

ID ABB09217 standard; protein; 269 AA.
 XX ABB09217;
 AC
 XX
 DT 08-JUL-2002 (first entry)
 XX
 DE Human GPI-anchored isoform a protein SEQ ID NO:4.
 XX
 KM GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic;
 KM glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KM glial cell line derived neurotrophic factor; osteopontin; tumour;
 KM neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KM medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KM neuronal disorder; aberrant axonal sprouting.
 XX
 OS Homo sapiens.
 XX
 PN WO200162795-A1.
 XX
 PD 30-AUG-2001.
 XX
 PF 14-NOV-2000; 2000WO-FI000994.
 XX
 PR 21-FEB-2000; 2000FI-00000394.
 XX
 PA (LICE-) LICENTIA LTD.
 XX
 PI Airaksinen M, Saarma M, Poterlaev D, Lindahl M, Timmusk T;
 PI Rosal J;
 XX
 DR WPI: 2001-596722/67.
 DR N-PSDB; ABL51672.
 XX
 PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR) alpha4.
 XX
 PS Claim 9; Fig 21B; 143pp; English.
 XX
 CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,
 CC osteopontin, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
 CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the human GFRalpha 4 protein, designated GPI-anchored
 CC isoform a, from the present invention
 XX
 SQ Sequence 269 AA;
 Query Match 65.1%; Score 920.5; DB 4; Length 269;
 Best Local Similarity 78.3%; Pred. No. 1.9e-77;
 Matches 173; Conservative 11; Mismatches 34; Indels 3; Gaps 1;
 QY 27 GSASSTEGNRCTVEAAEACTADECCQALRSEYVAQCUGRAQMGWPGSCVSRRCERARLRPF 86
 DB 16 GSASSTEGNRCTVEAAEACTADECCQALRSEYVAQCUGRAQMGWPGSCVSRRCERARLRPF 72
 QY 87 AAGPAPLTHALLFCGCGEPACACERRRQTAPACAFSGPOLAPPSCUKPIIDRCERSRRCRP 146
 DB 73 AAGPAPLTHALLFCGCGEPACACERRRQTAPACAFSGPOLAPPSCUKPIIDRCERSRRCRP 132
 QY 147 RLPAPGASCAPAPGSRIDCGEBEGPRCLAYAGLVGTVTTPYLDIVSARVAPWCCEAS 206

DB 133 RLAFQVSTPAPSPADGCLDQGARCLRAYAGLVGTATTPHYVDVNSARVAPKDCGAS 192
 QY 207 GNRRECEAFRLFTFRNPCLDGAIOAFDSSQPSVLODQNP 247
 DB 193 GNRREDCEAFRLFTFRNPCLDGAIOAFDSSQPSVLODQNP 233
 RESULT 11
 AAB62105
 ID AAB62105 standard; protein; 282 AA.
 AC AAB62105;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE Human RetL5 polypeptide.
 XX
 KM Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; human;
 KM vulnerrary; noctropic; anti-HIV; neuroprotective; antibacterial;
 KM cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..20
 FT /note="signal peptide"
 FT Protein 21..282
 FT /note="mature protein"
 XX
 PN WO200116169-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 01-SEP-2000; 2000WO-US024111.
 XX
 PR 01-SEP-1999; 99US-0152024P.
 XX
 PA (BIOV) BIOGEN INC.
 XX
 PI Worley D;
 XX
 DR WPI: 2001-235091/24.
 DR N-PSDB; AAF57272.
 XX
 PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor
 PT cell that expresses Ret and for modulating Ret signal transduction
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
 XX
 PS Claim 13; Fig 6; 76pp; English.
 XX
 CC The invention relates to mouse and human Ret ligand 5 (RetL5)
 CC polypeptides. The RetL5 polypeptides can be expressed by standard
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a
 CC dimerization or autophosphorylation activator. The polypeptides and their
 CC antibodies are useful for stimulating growth of or limiting damage to,
 CC Ret expressing tissue in a subject, for suppressing growth of a tumor
 CC cell that expresses Ret, for modulating Ret signal transduction involving
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion
 CC proteins containing RetL5 and antibodies are useful for stimulating renal
 CC tissue growth and/or survival, supporting renal function and minimizing
 CC damage to renal tissue after various insults, particularly for treating
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic
 CC syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic
 CC injury and trauma. The compounds are also useful for treating conditions
 CC such as neural degeneration where neural growth and regeneration are
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The
 CC compounds are also useful for treating disorders due to damage to neural
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events

CC such as hemorrhage or emboli, and neural disorders such as mental
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral
 CC palsy. The present sequence represents the human Kelt5 polypeptide
 XX
 SQ Sequence 282 AA;

Query Match 64.7%; Score 914.5; DB 4; Length 282;
 Best Local Similarity 74.6%; Pred. No. 7.4e-77;
 Matches 173; Conservative 15; Mismatches 41; Indels 3; Gaps 1;

QY 27 GSASTEGNRCVEAEACTADECCQQLRSEVVAQCLGRAGKRGSCYRSRCRRLRRFF 86
 DB 16 GSASSVGNRCVDAEACTADARCCQRLRSEVVAQCLGRA--AAGGCRARCRRLRRFF 72
 QY 87 ARGPPALTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCLKPLDRCSRRCRP 146
 DB 73 ARGPPALTHALLFCGACGACAEERRRQTFVPSCAFSGGPPAPPSCLEPINFCSRRVCRP 132
 QY 147 RLFAFQASCAPAGSRDGCPEEGPRCLRAYAGLVGTVPYVLNNVSARVAPWCGCEAS 206
 DB 133 RLFAFQASCTPAPSPADGCLDQGARCLRAYAGLVGTAVTPYVNVVSARVAPWCDGAS 192
 QY 207 GNRRECEAFRLFTFRNPCLDGAIOAFDSSQPSVLDQWNPYQNAQAKVEA 258
 DB 193 GNRREDCEAFRLFTFRNRCLGAIQAFASGWPVLLDQINPGDPEHSLQ 244

RESULT 12
 ABB09218
 ID ABB09218 standard; protein; 299 AA.

AC ABB09218;
 DT 08-JUL-2002 (first entry)
 DE Human putative GPI-anchored isoform b protein SEQ ID NO:5.

XX GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic;
 KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.

OS Homo sapiens.

XX WO200162795-A1.

PD 30-AUG-2001.

PF 14-NOV-2000; 2000WO-FI000994.

PR 21-FEB-2000; 2000FI-00000394.

PA (LICE-) LICENTIA LTD.

PI Airksinen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
 PI Rossi J;

OS MPI; 2001-596722/67.

DR N-PSDB; ABL51673.

PT New nucleic acid sequence for manufacturing polypeptides for treating
 PT endocrine cancers comprises a cDNA encoding a splicing isoform of
 PT mammalian growth factor receptor (GFR)alpha4.

PS Claim 9; Fig 22B; 143pp; English.

CC The present invention describes an isolated and purified cDNA sequence
 CC encoding a splicing isoform of a mammalian growth factor receptor
 CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytosolic,
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
 CC polynucleotide sequence can be used for recoding GFRalpha4 mediated
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and
 CC polynucleotide sequences can be used for manufacturing polypeptides
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,
 CC neoplasia, endocrine tumours, medullary thyroid carcinoma and
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
 CC preventing neuronal death or aberrant axonal sprouting. The present
 CC sequence represents the human GFRalpha 4 protein, designated putative GPI
 CC -anchored isoform b, from the present invention

XX Sequence 299 AA;

Query Match 54.3%; Score 767.5; DB 4; Length 299;
 Best Local Similarity 62.5%; Pred. No. 4.1e-63;
 Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

QY 27 GSASTEGNRCVEAEACTADECCQQLRSEVVAQCLGRAGKRGSCYRSRCRRLRRFF 86
 DB 16 GSASSVGNRCVDAEACTADARCCQRLRSEVVAQCLGRA--AAGGCRARCRRLRRFF 72
 QY 87 ARGPPALTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCLKPLDRCSRRCRP 145
 DB 73 ARGPPALTHALLFCGACGACAEERRRQTFVPSCAFSGGPPAPPSCLEPINFCSRRVCRP 132
 QY 146 -----PRLFAFQASCAPAGSRDGCPEEGPRCLRAY 177
 DB 133 ARAAAGPWRGWRGLSPAHRRPPAAQASPPGLSGLVHPSAQPRRLPAGPRPLPALRLGP 192
 QY 178 AGL-VGTVVTPYVLDNVSARVAPWCGCEASGNRRECEAFRLFTFRNPCLDGAIOAFDSS 236
 DB 193 RGVPAAGTAVTPYVNVVSARVAPWCDGASGNRRECEAFRLFTFRNPCLDGAIOAFASG 252
 QY 237 QPSVLDQWNP 247
 DB 253 WPVLLDQINP 263

RESULT 13
 ABB09219
 ID ABB09219 standard; protein; 182 AA.

AC ABB09219;

DT 08-JUL-2002 (first entry)

DE Human putative soluble isoform c protein SEQ ID NO:6.

XX GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic;
 KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;
 KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;
 KW neuronal disorder; aberrant axonal sprouting.

OS Homo sapiens.

XX WO200162795-A1.

PD 30-AUG-2001.

PF 14-NOV-2000; 2000WO-FI000994.

PR 21-FEB-2000; 2000FI-00000394.

PA (LICE-) LICENTIA LTD.

PI Airksinen M, Saarna M, Poterlaev D, Lindahl M, Timmusk T;
 PI Rossi J;

XX

Search completed: January 26, 2005, 13:12:23
Job time : 160 secs

```

DE Mouse Gdnf family receptor alpha 4 transmembrane isoform protein.
XX
XX Mouse; cytostatic; antiinflammatory; immunoregulatory; tissue integrity;
XX wound healing; immune response; vaccine; cancer; asthma; allergy;
XX Gdnf family receptor alpha 4 transmembrane isoform; cell trafficking;
XX therapy; Gfira4; secreted protein.
XX
OS Mus sp.
XX
XX MO200148192-A1.
XX
XX 05-JUL-2001.
XX
XX 21-DEC-2000; 2000WO-NZ000256.
XX
XX 23-DEC-1999; 99US-017678P.
XX
XX 28-NOV-2000; 2000US-00724864.
XX
XX (GENE-) GENESIS RES & DEV CORP LTD.
XX
XX Watson JD, Marison JG;
XX
XX WPI; 2001-425665/45.
XX
XX N-PSDB; AAD10139.
XX
XX Novel isolated polypeptide useful to isolate corresponding interacting
XX proteins or other compounds, to quantitatively determine levels of
XX interacting proteins or other compounds, and as therapeutic target.
XX
XX Claim 6; Page 93; 101pp; English.
XX
XX The patent discloses novel polynucleotides and their corresponding
XX proteins which play a major role in induction of growth, cell migration
XX and proliferation, cell-cell interaction and the differentiation of
XX tissue-specific cells. These proteins are important in the maintenance of
XX tissue integrity and thus are important in wound healing. They are useful
XX in various assays to determine the biological activity, to raise
XX antibodies, to isolate corresponding interacting proteins or other
XX compounds, to quantitatively determine levels of interacting proteins or
XX other compounds, and as therapeutic target in a whole range of disease
XX states. Compositions comprising the novel proteins of the invention are
XX useful for treating mammalian disorders. Polynucleotides of the invention
XX are useful in genome and physical mapping, in positional cloning of
XX genes, to tag or identify an organism or its reproductive material (as
XX non-disruptive tags for marking organisms), and for the diagnosis and
XX treatment of mammalian diseases which is the consequence of inappropriate
XX expression of kinase genes. They are useful for promoting immune response
XX as part of a vaccine or anti-cancer treatment, as target for cancer
XX treatment, as immunoregulatory and anti-inflammatory molecule, as
XX diagnostic for specific types of cancer and for development of an anti-
XX cancer treatment, and as a target for antagonists in the treatment of
XX diseases such as asthma and allergy. They are also useful to inhibit or
XX enhance the activity of the soluble molecule that binds proteins of the
XX invention, for tissue and neural regeneration, to promote or block cell
XX trafficking, and as anti-inflammatory and/or vaccine adjuvant. The
XX present sequence is mouse Gdnf family receptor alpha 4 (Gfira4)
XX transmembrane isoform
XX
SQ Sequence 132 AA;

Query Match      36.4%; Score 515; DB 4; Length 132;
Best Local Similarity 94.0%; Pred. No. 5,6e-40;
Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

OY 145 RPRLAFQASCAPAGSRDGCPEGGRCLRAYAGTGTVTPTNTLDNVSARVAPWCGCE 204
DB 9 RPRLAFQASCAPAGSRDGCPEGGRCLRAYAGTGTVTPTNTLDNVSARVAPWCGCA 68

OY 205 ASGNRRECEAFRKLTFTNPCLDGA10AFDSSQPSVLQDO 244
DB 69 ASGNRRECEAFRKLTFTNPCLDGA10AFDLSQPSVLQDO 108

```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 26, 2005, 13:05:31 ; Search time 41 Seconds
(without alignments)
605,462 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MMSGAYLVKLVNERPGQAVLM.....SYLDQDNMRYQNAQAKYEA 258

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 79:*

1: PIR1:*
2: PIR2:*
3: PIR3:*
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|----------|---------------------|
| 1 | 364.5 | 25.8 | 397 | 2 JE0082 | GPI-linked recepto |
| 2 | 130.5 | 9.2 | 3635 | 2 T10053 | laminin alpha 5 ch |
| 3 | 124.5 | 8.8 | 1959 | 1 AGRT | agrin - rat |
| 4 | 124 | 8.8 | 1574 | 2 T13954 | MEGR6 protein - ra |
| 5 | 123.5 | 8.7 | 1964 | 2 T09059 | notch4 - mouse |
| 6 | 122 | 8.6 | 4006 | 2 T09070 | probable tenascin |
| 7 | 118.5 | 8.4 | 1797 | 2 A55677 | laminin beta-2 cha |
| 8 | 116 | 8.2 | 384 | 2 S25771 | gaal protein - mou |
| 9 | 116 | 8.2 | 2321 | 2 S78549 | notch3 protein - h |
| 10 | 114 | 8.1 | 686 | 2 JCT769 | Delta-4 protein - |
| 11 | 114 | 8.1 | 1220 | 2 A56136 | jagged protein pre |
| 12 | 113 | 8.0 | 572 | 2 T29880 | hypothetical prote |
| 13 | 112.5 | 8.0 | 1372 | 2 T25933 | hypothetical prote |
| 14 | 110.5 | 7.8 | 476 | 2 A36478 | surface glycoprote |
| 15 | 110 | 7.8 | 4135 | 2 T42629 | tenascin-X - bovin |
| 16 | 109.5 | 7.7 | 1798 | 2 S53869 | laminin beta-2 cha |
| 17 | 108.5 | 7.7 | 2318 | 2 S45306 | notch 3 protein - |
| 18 | 108 | 7.6 | 2918 | 2 A54105 | fibritillin-2 precu |
| 19 | 107.5 | 7.6 | 1203 | 2 A49175 | Notch B protein - |
| 20 | 107.5 | 7.6 | 1955 | 1 AGCH | agrin precursor - |
| 21 | 107.5 | 7.6 | 2471 | 2 A49128 | cell-fate determin |
| 22 | 107 | 7.6 | 2531 | 2 A46019 | notch-1 protein - |
| 23 | 107 | 7.6 | 3566 | 1 A40701 | tenascin-X precurs |
| 24 | 106 | 7.5 | 335 | 2 T31560 | hypothetical prote |
| 25 | 105.5 | 7.5 | 1184 | 2 A55184 | fibritillin-2 precu |
| 26 | 105.5 | 7.5 | 1801 | 1 MMRTS | laminin beta-2 cha |
| 27 | 105.5 | 7.5 | 2555 | 2 A40043 | notch protein homo |
| 28 | 104.5 | 7.4 | 242 | 2 T29699 | hypothetical prote |
| 29 | 104.5 | 7.4 | 335 | 2 T31561 | hypothetical prote |

| | | | | | |
|----|-------|-----|------|----------|-----------------------|
| 30 | 104.5 | 7.4 | 3672 | 2 T23433 | hypothetical prote |
| 31 | 104.5 | 7.4 | 3704 | 2 T37316 | probable laminin a |
| 32 | 104 | 7.4 | 345 | 2 A53138 | gaal homolog - hum |
| 33 | 103.5 | 7.3 | 335 | 2 T31559 | hypothetical prote |
| 34 | 103.5 | 7.3 | 425 | 2 T18592 | hypothetical prote |
| 35 | 103.5 | 7.3 | 2769 | 1 UIBO | chrysotholubulin prec |
| 36 | 103 | 7.3 | 2139 | 2 A35672 | crumbs protein - f |
| 37 | 102.5 | 7.3 | 600 | 2 T18593 | hypothetical prote |
| 38 | 102.5 | 7.3 | 1664 | 2 A40136 | fibritillin 1a - s |
| 39 | 102 | 7.2 | 2531 | 2 S18188 | notch protein homo |
| 40 | 101 | 7.1 | 2524 | 2 A35844 | Notch protein - Af |
| 41 | 100 | 7.1 | 728 | 2 T20561 | hypothetical prote |
| 42 | 100 | 7.1 | 2907 | 2 A57278 | fibritillin-2 precu |
| 43 | 100 | 7.1 | 3075 | 2 S14458 | laminin alpha-1 ch |
| 44 | 99 | 7.0 | 1620 | 2 T27283 | hypothetical prote |
| 45 | 99 | 7.0 | 2352 | 2 T30201 | Notch homolog prot |

ALIGNMENTS

```

RESULT 1
JE0082
GPI-linked receptor precursor - mouse
N:Alternate names: GFRalpha-3
C:Species: Mus musculus (house mouse)
C:Date: 21-May-1998 #sequence_revision 29-May-1998 #text_change 09-Jul-2004
C:Accession: JE0082
R:Nomoto, S.; Ito, S.; Yang, L.X.; Kiyuchi, K.
Biochem. Biophys. Res. Commun. 244, 849-853, 1998
A:Title: Molecular cloning and expression analysis of GFRalpha-3, a novel cDNA related to
A:Reference number: JE0082; M0ID:98205811; PMID:9535755
A:Accession: JE0082
A:Molecule type: mRNA
A:Residues: 1-397 <NOM>
A:Cross-references: UNIPROT:Q35118; DBJ:AB008833; NID:92627159; PIDN:BA23562.1; PID:92627159
C:Comment: This protein plays a distinct role in cell survival and differentiation.
C:Superfamily: Mus musculus GPI-linked receptor
C:Keywords: glycoprotein
F:1-25/Domain: signal sequence #status predicted <SIG>
F:380-397/Region: hydrophobic
F:92,145,306/Binding site: carbohydrate (asn) (covalent) #status predicted

Query Match      25.8%; Score 364.5; DB 2; Length 397;
Best Local Similarity 35.1%; Pred. NO. 8,4e-23;
Matches 86; Conservative 26; Mismatches 102; Indels 31; Gaps 7;

QY 20 WSLGQSGSASTEGNRCVEAAEACTADQCQQLRSEVVAOCLGRAGMRGPGSCVRSRGR 79
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 142 WKNUNSKLMLKRPDSDCLKPFMLCTLHDKCDRLKAYGEACSGI-----RCQRHLCL 194
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 80 RALRRFPFARGPALTHALFFCG--EGPACAEERRQTFAPACAFSGPOLAPSPCLPLDR 137
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 195 AQLRSFPEKAASHAQGLLCPACAPDAGCGRRRNTIAPSCALRS---VTNCDLRSP 251
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 138 CERSRRCRPLFAFQASCAPAP--GSRDCCPEEGRCIRAYAGLVGVTVTVNYLDNVA 195
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 252 CQADPLCRSLMDFOTHCHPMDILGT---CATEQS-RCIRAYLIGLIGTAMTNFISKVNT 307
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 196 RYAPMCGCASGNRRBECEAPRKLFTPNPCLDGALQIA-----PDSSQPSVVO 242
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 308 TVALSTCRGSGNLQDECEQLERSFSQNPCLVEAIAAKRFRRLQFSGQMDSTFSVVO 367
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 243 DQWNP 247
   |||  : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 368 QNSNP 372

RESULT 2
T10053
laminin alpha 5 chain - mouse (fragment)
C:Species: Mus musculus (house mouse)
C:Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #text_change 09-Jul-2004

```

C:Accession: T10053
 R:Miner, J.H.; Lewis, R.M.; Sanes, J.R.
 submitted to the EMBL Data Library, November 1997
 A:Reference number: Z16923
 A:Accession: T10053
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-3635 <MIN>
 A:Cross-references: UNIPROT:Q61001; EMBL:U37501; NID:g2599231; PID:g2599232
 C:Genetics:
 A:Gene: Lama5
 C:Keywords: Basement membrane; cell binding; extracellular matrix
 F:1888-1939/Domain: laminin-type EGF-like homology <LEG>
 F:1942-1970/Domain: EGF homology <EGF>

Query Match
 Best Local Similarity 9.2%; Score 130.5; DB 2; Length 3635;
 Matches 65; Conservative 21; Mismatches 97; Indels 135; Gaps 12;

24 CORGSASTREG-----NRCVEAAGC-----TADGCGQQLSEYVA--- 59
 1763 CARGYRDTKGLFLGRVCPQCHGSHDRCLPSSGICVCGQNTBEGQCRCPGVSSDP 1822
 60 -----QCLGRAGMRGPGSCVNSRCRRALRRFFA 87
 1823 SNPASPCVSCPCLAVPSNNFADGCVLRNGRTQCLCRPGYAG-----ASCRCAPGFFG 1876
 88 RRPPLTHALLFCGEG-----PACARRRQTFAPAC-----AFSGPOLA 127
 1877 -NPLVIGSSQPCPCDSGNGDPNMFSDCDPLTGACRGCLRHYYGHGRCARPGFGMLT 1935
 128 PPSCLK-----PLDRC-----ERSRRCRPLFAFO-----ASCAPAP 159
 1936 PGNCTRCCSPCGTETCDPQSGRLCKAKAVTGQRCDRLCEGFEGECQCGCPACGPA 1995
 160 GSRDCCPEBG-----GPRCLRAYAGLVGTVTTPNYLDNVSARVAPWCGCEASGNRR 210
 1996 KQSECHPQSGQCHCPGTTGPGQLECAPGYWG-----LPKGCRCRCQCPR 2040
 211 EECBAFRKLFTNPNCLDG 228
 2041 GHCDPHTHGHTCPPLSG 2058

Db

RESULT 3
 AGRT
 agrin - rat
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
 A:Accession: JH0399; A38856
 R:Rupp, F.; Payan, D.G.; Magill-Sole, C.; Cowan, D.M.; Scheller, R.H.
 Neuron 6, 811-823, 1991
 A:Title: Structure and expression of a rat agrin.
 A:Reference number: JH0399; MUID:91222570; PMID:1851019
 A:Accession: JH0399
 A:Molecule type: mRNA
 A:Residues: 1-1779,1799-1959 <RUP>
 A:Cross-references: UNIPROT:g25304; GB:M64780; NID:g202798; PIDD:AAA40703.1; PID:g202800
 A:Experimental source: embryonic spinal cord
 A>Note: it is uncertain whether Met-1, Met-18, or Met-24 is the initiator
 R:Rupp, F.; Oezcelik, T.; Linial, M.; Petersen, K.; Francke, U.; Scheller, R.
 J. Neurosci. 12, 3535-3544, 1992
 A:Title: Structure and chromosomal localization of the mammalian agrin gene.
 A:Reference number: A38856; MUID:92407628; PMID:1326608
 A:Accession: A38856
 A:Molecule type: mRNA
 A:Residues: 1760-1798 <RU2>
 A:Cross-references: GB:S44194
 C:Comment: This protein mediates the motor neuron-induced aggregation of acetylcholine r
 ycholine receptor clustering activity.
 C:Superfamily: agrin; EGF homology; Kazal proteinase inhibitor homology; laminin G repe
 C:Keywords: alternative splicing; duplication; glycoprotein; neuromuscular junction

F:1-1959/Product: agrin, form 1 #status predicted <AG1>
 F:1-1787,1799-1959/Product: agrin, form 4 #status predicted <AG4>
 F:1-1779,1799-1959/Product: agrin, form 3 #status predicted <AG3>
 F:1-1779,1798-1959/Product: agrin, form 5 #status predicted <AG5>
 F:1-1143,1153-1959/Product: agrin, form 2 #status predicted <AG2>
 F:2-50/Region: hydrophobic
 F:88-137/Domain: Kazal proteinase inhibitor homology <KP11>
 F:163-212/Domain: Kazal proteinase inhibitor homology <KP12>
 F:236-284/Domain: Kazal proteinase inhibitor homology <KP13>
 F:307-356/Domain: Kazal proteinase inhibitor homology <KP14>
 F:381-429/Domain: Kazal proteinase inhibitor homology <KP15>
 F:446-494/Domain: Kazal proteinase inhibitor homology <KP16>
 F:511-559/Domain: Kazal proteinase inhibitor homology <KP17>
 F:540-542/Region: motor neuron attachment (L-R-E) motif
 F:596-645/Domain: laminin-type EGF-like homology <LE1>
 F:688-739/Domain: laminin-type EGF-like homology <LE2>
 F:742-786/Domain: laminin-type EGF-like homology <LE2>
 F:814-864/Domain: Kazal proteinase inhibitor homology <KP19>
 F:869-992/Region: serine/threonine-rich
 F:1084-1086/Region: motor neuron attachment (L-R-E) motif
 F:1147-1215/Region: serine/threonine-rich
 F:11224-1257/Domain: EGF homology <EG1>
 F:11247-1442/Domain: laminin G repeat homology <LG1>
 F:1144-1476/Domain: EGF homology <EG2>
 F:11483-1515/Domain: EGF homology <EG3>
 F:11555-1706/Domain: laminin G repeat homology <LG2>
 F:11713-1747/Domain: EGF homology <EG4>
 F:11807-1959/Domain: laminin G repeat homology <LG3>
 F:197-116,105-137,171-191,180-212,244-263,252-284,316-335,324-356,389-408,397-429,454-473
 F:1476,1483-1494,1488-1504,1506-1515/disulfide bonds: #status predicted
 F:145,672,827,957/Binding site: carbohydrate (Aan) (covalent) #status predicted

Query Match
 Best Local Similarity 8.8%; Score 124.5; DB 1; Length 1959;
 Matches 56; Conservative 25; Mismatches 111; Indels 51; Gaps 11;

25 ORGSASTEGNRCEAABACTADEQCOQLRSEYVAOCLRAG-W---RPGSCVRSRCCR 80
 552 EEAHAGCEPACSGSSGSGGDEDEQ-----ELCRQKGIWDESEBQPCVCDPSQ 605
 81 ALRRFARGPPLTHALLFCGCEGPACARRRQTFAPACAFSGPOLAP-----PSCLKP 134
 606 SVPRSPVCGSDGYTG-TECDLKKARCESQDELVAAGACRGPTLAPLPVAFPHCAQT 664
 135 -----LDRERSRRCRPLFAPQASCAPRPGSDGCPBEGCPCLAPYA 178
 665 PYGCCQDNFTAAQGVAGGCPSTCHCNPH-GSYSGTCDPATGQSCRPVGVGRLCDRCBP 723
 179 GL-VGTVTTPNYLDNVSARVAPWCGCEASGNRRECEAPRKLFTNPN-----CLD 227
 724 GFNMFRTIVTDG-----SGCTP-CSCDPRGAVRDDCEQMTGLCSRPVAVGPKCGCCPD 777

Db

RESULT 4
 T13954
 ME6E protein - rat
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
 A:Accession: T13954
 R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.
 Genomics 51, 27-34, 1998
 A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs
 A:Reference number: Z14126; MUID:98360089; PMID:9693030
 A:Accession: T13954
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-1574 <NAK>
 A:Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:g3449293; PIDD:BA32462.1; PID:g3
 A:Experimental source: strain Sprague-Dawley; brain

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using bw model

Run on: January 26, 2005, 13:15:47 ; Search time 147 Seconds
(without alignments)
634.100 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413
Sequence: 1 MLSGAYLRLNERPGQAVLWSVLDDQWNPYQNAQAKVEA 258

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1608061 seqs, 361289386 residues

Total number of hits satisfying chosen parameters: 1608061

```
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
```

| | | |
|------------------|---------------|--------------|
| Post-processing: | Minimum Match | 0% |
| | Maximum Match | 100% |
| | Listing first | 45 summaries |

Published Applications AA:*

- 1: /cgn2_6/prodataa1/pubppa/US07_PUBCOMB.pcp:*
- 2: /cgn2_6/prodataa1/pubppa/PCT_NEW_PUB.pcp:*
- 3: /cgn2_6/prodataa1/pubppa/US06_NEW_PUB.pcp:*
- 4: /cgn2_6/prodataa1/pubppa/US07_NEW_PUB.pcp:*
- 5: /cgn2_6/prodataa1/pubppa/PCTUS_PUBCOMB.pcp:*
- 6: /cgn2_6/prodataa1/pubppa/US08_NEW_PUB.pcp:*
- 7: /cgn2_6/prodataa1/pubppa/US09_PUBCOMB.pcp:*
- 8: /cgn2_6/prodataa1/pubppa/US09A_PUBCOMB.pcp:*
- 9: /cgn2_6/prodataa1/pubppa/US09B_PUBCOMB.pcp:*
- 10: /cgn2_6/prodataa1/pubppa/US09C_PUBCOMB.pcp:*
- 11: /cgn2_6/prodataa1/pubppa/US09C_PUBCOMB.pcp:*
- 12: /cgn2_6/prodataa1/pubppa/US09_NEW_PUB.pcp:*
- 13: /cgn2_6/prodataa1/pubppa/US10_PUBCOMB.pcp:*
- 14: /cgn2_6/prodataa1/pubppa/US10C_PUBCOMB.pcp:*
- 15: /cgn2_6/prodataa1/pubppa/US10C_PUBCOMB.pcp:*
- 16: /cgn2_6/prodataa1/pubppa/US10_PUBCOMB.pcp:*
- 17: /cgn2_6/prodataa1/pubppa/US10_NEW_PUB.pcp:*
- 18: /cgn2_6/prodataa1/pubppa/US11_NEW_PUB.pcp:*
- 19: /cgn2_6/prodataa1/pubppa/US60_NEW_PUB.pcp:*
- 20: /cgn2_6/prodataa1/pubppa/US60_PUBCOMB.pcp:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|--------------------|
| 1 | 515 | 36.4 | 132 | 10 | US-09-866-050A-709 |
| 2 | 469 | 33.2 | 445 | 16 | US-10-673-007-11 |
| 3 | 469 | 33.2 | 460 | 17 | US-10-872-161-40 |
| 4 | 469 | 33.2 | 464 | 9 | US-09-388-316-6 |
| 5 | 469 | 33.2 | 454 | 14 | US-10-357-832-6 |
| 6 | 469 | 33.2 | 464 | 16 | US-10-673-007-2 |
| 7 | 469 | 33.2 | 664 | 9 | US-09-388-316-18 |
| 8 | 469 | 33.2 | 664 | 14 | US-10-357-832-18 |
| 9 | 465 | 32.9 | 460 | 14 | US-10-241-220-62 |
| 10 | 465 | 32.9 | 460 | 17 | US-10-872-972-62 |
| 11 | 465 | 32.9 | 460 | 17 | US-10-872-991-62 |
| 12 | 465 | 32.9 | 463 | 14 | US-10-155-693-10 |
| 13 | 465 | 32.9 | 463 | 14 | US-10-155-693-12 |

| | | | | | | |
|----|-------|------|-----|----|--------------------|---------------------|
| 14 | 465 | 32.9 | 463 | 17 | US-10-872-161-10 | Sequence 10, Appl |
| 15 | 465 | 32.9 | 463 | 17 | US-10-872-161-12 | Sequence 12, Appl |
| 16 | 465 | 32.9 | 465 | 14 | US-10-357-622-22 | Sequence 22, Appl |
| 17 | 465 | 32.9 | 465 | 14 | US-10-155-693-2 | Sequence 2, Appl |
| 18 | 465 | 32.9 | 465 | 14 | US-10-155-693-6 | Sequence 6, Appl |
| 19 | 465 | 32.9 | 465 | 14 | US-10-285-027-84 | Sequence 84, Appl |
| 20 | 465 | 32.9 | 465 | 15 | US-10-058-670A-24 | Sequence 24, Appl |
| 21 | 465 | 32.9 | 465 | 16 | US-10-673-007-8 | Sequence 8, Appl |
| 22 | 465 | 32.9 | 465 | 17 | US-10-872-161-2 | Sequence 2, Appl |
| 23 | 465 | 32.8 | 465 | 17 | US-10-872-161-6 | Sequence 6, Appl |
| 24 | 463 | 32.8 | 468 | 17 | US-10-872-161-56 | Sequence 56, Appl |
| 25 | 462 | 32.7 | 464 | 9 | US-09-388-316-3 | Sequence 3, Appl |
| 26 | 462 | 32.7 | 464 | 14 | US-10-357-622-3 | Sequence 3, Appl |
| 27 | 462 | 32.7 | 464 | 16 | US-10-673-007-9 | Sequence 9, Appl |
| 28 | 462 | 32.7 | 464 | 17 | US-10-723-660-3950 | Sequence 1950, Appl |
| 29 | 462 | 32.7 | 468 | 14 | US-10-033-350-2 | Sequence 2, Appl |
| 30 | 462 | 32.7 | 468 | 14 | US-10-357-622-21 | Sequence 21, Appl |
| 31 | 462 | 32.7 | 468 | 14 | US-10-155-693-4 | Sequence 4, Appl |
| 32 | 462 | 32.7 | 468 | 16 | US-10-673-007-1 | Sequence 1, Appl |
| 33 | 462 | 32.7 | 468 | 17 | US-10-872-161-4 | Sequence 4, Appl |
| 34 | 462 | 32.7 | 664 | 9 | US-09-388-316-5 | Sequence 16, Appl |
| 35 | 462 | 32.7 | 664 | 14 | US-10-357-622-16 | Sequence 16, Appl |
| 36 | 461 | 32.6 | 464 | 17 | US-10-872-161-36 | Sequence 36, Appl |
| 37 | 432.5 | 30.6 | 489 | 17 | US-10-872-161-43 | Sequence 43, Appl |
| 38 | 422.5 | 29.9 | 498 | 17 | US-10-872-161-43 | Sequence 43, Appl |
| 39 | 399 | 28.2 | 232 | 14 | US-10-155-693-13 | Sequence 14, Appl |
| 40 | 399 | 28.2 | 232 | 17 | US-10-872-161-14 | Sequence 14, Appl |
| 41 | 399 | 28.2 | 294 | 14 | US-10-155-693-15 | Sequence 16, Appl |
| 42 | 399 | 28.2 | 294 | 17 | US-10-872-161-16 | Sequence 16, Appl |
| 43 | 376 | 26.6 | 397 | 17 | US-10-872-161-42 | Sequence 42, Appl |
| 44 | 364.5 | 25.8 | 397 | 9 | US-09-220-920-64 | Sequence 64, Appl |
| 45 | 361 | 25.5 | 400 | 9 | US-09-220-920-53 | Sequence 63, Appl |

ALIGNMENTS

```

RESULT 1
US-09-866-050A-709
Sequence 709, Application US/098666050A
Publication No. US20030040471A1
GENERAL INFORMATION:
APPLICANT: Watson, James D.
APPLICANT: Strachan, Iorna
APPLICANT: Sleeman, Matthew
APPLICANT: Onrust, Rene
APPLICANT: Murison, James G.
APPLICANT: Kumble, Krishanand D.
TITLE OF INVENTION: Compositions Isolated From Skin Cells
TITLE OF INVENTION: and Methods for Their Use
FILE REFERENCE: 11000.10114U
CURRENT APPLICATION NUMBER: US/09/866,050A
NUMBER OF SEQ ID NOS: 725
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 709
LENGTH: 132
TYPE: PRT
ORGANISM: Mouse
US-09-866-050A-709

```

| | Query Match | Best Local Match | Similarity | Score | DB | Length |
|---------|-------------|------------------|---|-------|-----------------|--------------------------------|
| Matches | 94 | Conservative | 96.4% | 34.0% | Pred. No. 1e-36 | Mismatches 5; Indels 0; Gaps 0 |
| Qy | 145 | REPILAFPOASCAPA | PSRDCPEEGPCPLRAYAGLNTVTTPYINLVNSARVAPMGCE | 204 | | |
| Db | 9 | REPILAFPOASCAPA | PSRDCPEEGPCPLRAYAGLNTVTTPYINLVNSARVAPMGCA | 68 | | |
| Qy | 205 | ASGNRRBECBAFRKL | FTTRNPCLDGAIOAFDSQSPVLDDQ | 244 | | |
| Db | 69 | ASGNRRBECBAFRKL | FTTRNPCLDGAIOAFDSQSPVLDDQ | 108 | | |

RESULT 7 US-09-388-316-18
; Sequence 18, Application US/09388316
; Publication No. US20020051972A1
; GENERAL INFORMATION:
; APPLICANT: Robert D. Klein, Arnon Rosenenthal, Mary A. Hyneen
; TITLE OF INVENTION: Neurturin Receptor
; NUMBER OF SEQUENCES: 19

```

CORRESPONDENCE ADDRESS:
ADDRESS: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/368,316
FILING DATE: 01-Sep-1999
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/024,665
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/049818
FILING DATE: 9-Jun-1997
APPLICATION NUMBER: 60/038839
FILING DATE: 18-Feb-1997
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P106R3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEX: 650/952-9881
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 664 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-09-388-316-18
SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Query Match      33.2%   Score 469; DB 9; Length 664;
Best Local Similarity 43.0%; Pred. No. 5,2e-32;
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3

QY 29 ASSTEGNRGVAAAEKCTADECCQQQLRSERYVAQCCLGRAGMRGSGSVSRCAALRRFPAR 88
|||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::
Db 153 AVSTKSNNCLDPAAKACNLINDNCKLKRSSYSISTCNREIS--PTERCNRKKCHVALRFQFDR 210
QY 89 GPPLATHALLFCGCGEGPACARERRROTFAFAPACAFSGPOLAPPSCLELDRCERSRRCRPRL 148
|||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::
Db 211 VPSEYTRMLTCSQODQACABRRRTITLPSCSYENKE--KNKCLDLRLSLCRDHLCKRRL 268
QY 149 FAFQASCPAAGSRDGCPEBEGPRCLRAYVAGLVGTVPNTYIDN--VSARYAAPWGCCEAS 206
|||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::||||:::
Db 269 ADFFANCAASRYRTTSCPADNYOALGTSYAGWIGFDMPNTYDSNPITIVVSPWCNCRGS 328
QY 207 GNREECEGAFFKLFTFNPCLDGAIOAF 233
||| ||| | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 329 GNMEBECEKFLRDFTENPCLNMAIOAF 355

RESULT 8
US-10-357-822-18
Sequence 18, Application US/10357822
Publication No. US20030110525A1
GENERAL INFORMATION:
APPLICANT: KLEIN, ROBERT D.
APPLICANT: ROSENTHAL, ARNON
APPLICANT: HYNES, MARY A.
TITLE OF INVENTION: NEURTURIN RECEPTOR
FILE REFERENCE: GENENT 45A2DV1
CURRENT FILING DATE: 2003-02-03
CURRENT FILING DATE: 2003-02-03
PRIORITY FILING DATE: US/09/388,316C
PRIORITY FILING DATE: 1999-09-01

```

```

? PRIOR APPLICATION NUMBER: 09/024,665
? PRIOR FILING DATE: 1998-02-17
? PRIOR APPLICATION NUMBER: 60/063,258
? PRIOR FILING DATE: 1997-10-24
? PRIOR APPLICATION NUMBER: 60/049,818
? PRIOR FILING DATE: 1997-06-09
? PRIOR APPLICATION NUMBER: 60/038,839
? PRIOR FILING DATE: 1997-02-18
? NUMBER OF SEQ ID NOS: 30
? SOFTWARE: FastSeq for Windows Version 4.0
? SEQ ID NO 18
? LENGTH: 664
? TYPE: PRT
? ORGANISM: Artificial Sequence
? FEATURES:
? OTHER INFORMATION: This sequence is a fusion protein comprising rat
? OTHER INFORMATION: NTRN1alpha sequence and human Fc sequence.
US-10-357-822-18

```

| | | | | |
|-----------------------|--------|--------------------|--------|----------------|
| Query Match | 33.2%; | Score 469; | DB 14; | length 664; |
| Best Local Similarity | 43.0%; | Pred. No. 5.2e-32; | | |
| Matches | 89; | Conservative | 33; | Mismatches 79; |
| | | | Indels | 6; |
| | | | Gaps | 3 |

| | | | |
|----|-----|--|-----|
| Qy | 29 | ASSTENRCVCEAAEATLDEQCQOLRSYVAQCLGRAGMRRPSSCVSRCPRLARRPEAR | 88 |
| Db | 153 | AVSTCKNHCCIDAKAKANLINDCKKLRSSAYISICBREIS--PTKCNRRKCHKALROFPDR | 210 |
| Qy | 89 | GPALTHALLFCGCEGPAEARRRQTFAPACAFSGPOLAPPSCLPKIDRCERSRCPRL | 148 |
| Db | 211 | VPESEYRYRLPFCSCQDQACERRRQTLIPSCSYEDKE--KNCICDLASLCTHILCKSRL | 268 |
| Qy | 149 | FAFQASCAPAFSGRDGCEBGGPRCLRAYAGLVGTVTTPNYLND--VSARVAPWCGCEAS | 206 |
| Db | 269 | ADENHANCRAASYRTITSCPADNYQAQCLGSGYAGMIGFDMTPNVVDNSPTGI VSPWCNCRGS | 328 |
| Qy | 207 | GNRRECEAFRLKLTFRNPLDGAIOAF | 233 |
| Db | 329 | GNNEECEKFLRDPTEINPCLRNAIOAF | 355 |

```

RESULT 9
US-10-241-220-62
; Sequence 62, Application US/10241220
; Publication No. US20030148408A1
; GENERAL INFORMATION:
; APPLICANT: Prantz, Gretchen
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Phillips, Heidi
; APPLICANT: Polakis, Paul
; APPLICANT: Spencer, Susan
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wu, Thomas
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
; TITLE OF INVENTION: TREATMENT OF TUMOR
; FILE REFERENCE: P5010R1-US
; CURRENT APPLICATION NUMBER: US/10/241,220
; NUMBER FILING DATE: 2002-12-13
; NUMBER OF SEQ ID NOS: 120
; SEQ ID NO 62
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Homo Sapien
; US-10-241-220-62

```

Query Match 32.9% Score 465 DB 14 Length 460;
Best Local Similarity 41.9% Pred. No. 7,88-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3

Oy 33 EGNRCVTAABACTADECCOOLRSTRYVAQCTAGACRGWBGSCVTRSCRRLATRRFPARGPPA 92
::: :::: : :::: :
Db 145 KANNCCIDAAACANLDDICTCKKRSAYRIPTCTSV--SNDVCNRRKKCHVALAQFDPKVAK 201
::: :::: : :::: :

```

0Y  LTHALLFGCGEPPACACERRRQTFAPACAPGSLAPSCILKPLDRCEBSRCBPRIEAFQ 152
0Y  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
Db  HSYGMLFSCGRICACTERRRQTTVPVCSE--EREPKRCNLTLQDSCCTWNTICSRILADF 259
0Y  153 ASCAPAPGSRDQCEPEGGPRCLRAAYAGLGTVTTPYULDNVSARVAPMCCEASGNREE 212
0Y  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
Db  260 TNCQPEBSRSVSSCLKENYADCLLAYSGLLGTWTPYIIRSSLSLVAPMCDCSNSGNDLEE 319
0Y  213 CEAFRKLFTFRNPLDGAIOAFDSSQPSYLODOWNP 247
Db  320 CLKFLNFPKDNCTLKRAIQAFNGSGVTV---WQP 351

```

```

RESULT 10
US-10-872-972-62
: Sequence 62. Application US/10872972
: Publication No. US20040229277A1
: GENERAL INFORMATION:
: APPLICANT: Frantz, Gretchen
: APPLICANT: Hylan, Kenneth J.
: APPLICANT: Phillips, Heidi
: APPLICANT: Polakis, Paul
: APPLICANT: Spencer, Susan
: APPLICANT: Williams, P. Mickey
: APPLICANT: Wu, Thomas
: APPLICANT: Zhang, Zemin
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
: TITLE OF INVENTION: TREATMENT OF TUMOR
: FILE REFERENCE: P5010R1-US
: CURRENT APPLICATION NUMBER: US/10/872,972
: CURRENT FILING DATE: 2004-06-21
: PRIOR APPLICATION NUMBER: US/10/241,220
: PRIOR FILING DATE: 2002-09-11
: NUMBER OF SEQ ID NOS: 120
: SEQ ID NO 62
: LENGTH: 460
: TYPE: PRT
: ORGANISM: Homo Sapien
US-10-872-972-62

```

| | | | | |
|-----------------------|-------|--------------------|-------|---------------------------------|
| Query Match | 32.9% | Score 465 | DB 17 | Length 460 |
| Best Local Similarity | 41.9% | Pred. No. 7, 8e-32 | | |
| Matches | 90 | Conservative | 30 | Mismatches 87, Indels 8, Gaps 3 |

| | | | |
|----|-----|---|-----|
| QY | 33 | EGNRCEVAAEACTABEQCOLRSEYVAQCLGRAGMRPGSCVRSRCRRLRRFFPAGPPA | 92 |
| Db | 145 | KGNMCLDAPAKACNMLDICCXYRSAYITPCTTSV---SNDVCNRRKKCHKLRQFFDKVPAP | 201 |
| QY | 93 | LTHALLPGCEBPACAEERRRQTFAPAPCAESGPOLAPSPCLKPLDRGERSRRCRPLPAFQ | 152 |
| Db | 202 | HSYGNLPGSCRDIACTERRRQTTVPACSYE--EREKPCNLTNODSCKTNTYICSRILADFF | 259 |
| QY | 153 | ASCAAPAGSRDQCEPEGGRCLRAVAGLVGTVTPYTLDNVSARVAAPMCCEASGNRREE | 212 |
| Db | 260 | TNCGESRSVSSTCKENYADCLLAYSGLIGTVMTPTYIDSSLSLSVAPMCCDSSGMDLEE | 319 |
| QY | 213 | CEAFRLKLFTRNRCIDGATAPAFSSQSGSVADQDNP | 247 |
| Db | 320 | CLKFLNFFKDNTCLKNALIDAFNGSGDVTV---WQP | 351 |

RESULT 11
US-10-872-991-62
Sequence 62, Application US/10872991
Publication No. US20040242860A1
GENERAL INFORMATION:
APPLICANT: Franz, Gretchen
APPLICANT: Hillan, Kenneth J.
APPLICANT: Phillips, Heidi
APPLICANT: Polakis, Paul
APPLICANT: Spencer, Susan
APPLICANT: Williams, P. Mickey
APPLICANT: Wu, Thomas

```

? APPLICANT: Zhang,Zemin
?
? TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
? TREATMENT OF TCMOR
?
? FILE REFERENCE: P5010R1-US
?
? CURRENT APPLICATION NUMBER: US/10/872,991
?
? CURRENT FILING DATE: 2004-06-21
?
? PRIOR APPLICATION NUMBER: US/10/241,220
?
? PRIOR FILING DATE: 2002-09-11
?
? NUMBER OF SEQ ID NOS: 120
?
? SEQ ID NO 62
?
? LENGTH: 460
?
? TYPE: PRT
?
? ORGANISM: Homo Sapien.
?
US-10-872-991-62

```

[illegible]

```

RESULT 12
US-10-155-693-10
; Sequence 10, Application US/10155693
; Publication No. US20030175876A1
; GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHUOIAN
; APPLICANT: WEN, DUANZHI
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPIC FACTOR RECEPTOR
; FILE REFERENCE: A-401C
; CURRENT APPLICATION NUMBER: US/10/155,693
; CURRENT FILING DATE: 2002-05-24
; PRIOR APPLICATION NUMBER: US/08/837,199
; PRIOR FILING DATE: 1997-04-14
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 463
; TYPE: PRt
; ORGANISM: HUMAN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser.
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(537)
; OTHER INFORMATION: No. US20030175876A1e="1 to 537 is -235 to 301 of Figure 5 21acom
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (550)..(550)
; OTHER INFORMATION: N in position 550 indicates any nucleic acid
US-10-155-693-10

```

RESULT 13
US-10-155-693-12
; Sequence 12, Application US/10155693
; Publication No. US20030175876A1

| | | | | |
|-------------|--------|------------|--------|-------------|
| Query Match | 32.9%; | Score 465; | DB 14; | Length 463; |
|-------------|--------|------------|--------|-------------|

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCV EAEACTADEQCQQLRSEYVAQCLGRAGWRGPGSCVRSRCRRALRRFFARGPPA 92

Db 150 KGNNC L D A K A C N L D D I C K K Y R S A Y I T P C T S V --- S N D V C N R R K C H K A L R Q F F D K V P A K 206

93 LTHALFCGCEGPACAERRÖTFAPACAFSGPQLAPPSCCLKPLDRCSRRCRPRLFAFQ 152

Db 207 HSYGMLFCSCRDIACTERRRQTI V P V C S Y E - - E R E K P N C L N L Q D S C K T N Y I C R S R L A D F F 264

QY 153 ASCAPAPGSRDGCPEEGPRCLRAYAGLVGVTPNYLDNV SARVAPWCGCEASGNREE 212

Db 265 TNCQPESSRSVSSCLKENYADCLLAYSGLIGVTMPNYIDSSLSVAPWCDCSNSGNDLEE 324

QY 213 CEA FRKLFT RNPCLDGA IQAFDSSQPSVLQDQWNP 247

Db 325 CLKFLNFKDNTCLKNAIQAFNGSDVTV---WQP 356

```

RESULT 14
US-10-872-161-10
? Sequence 10, Application US/10872161
? Publication No. US20040235714A1
? GENERAL INFORMATION:
? APPLICANT: FOX, GARY M.
? APPLICANT: JING, SHUOIAN
? APPLICANT: MEN, DUANZHI
? TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
? FILE REFERENCE: A-401D
? CURRENT APPLICATION NUMBER: US/10/0872,161
? CURRENT FILING DATE: 2004-06-18
? PRIOR APPLICATION NUMBER: US/08/866,354
? PRIOR FILING DATE: 1997-05-30
? PRIOR APPLICATION NUMBER: US 60/015,907
? PRIOR FILING DATE: 1996-04-22
? PRIOR APPLICATION NUMBER: US 60/017,221
? PRIOR FILING DATE: 1996-05-09
? PRIOR APPLICATION NUMBER: US 08/837,199
? PRIOR FILING DATE: 1997-04-14
? NUMBER OF SEQ ID NOS: 61
? SOFTWARE: PatentIn version 3.2
? SEQ ID NO 10
? LENGTH: 463
? TYPE: PRT
? ORGANISM: HUMAN
? FEATURE:
? NAME/KEY: misc feature
? LOCATION: (5)..(5)
? OTHER INFORMATION: The 'Xaa' at location 5 stands for Thr, Ala, Pro, or Ser
US-10-872-161-10

```

| | |
|-------------|--------------------------------------|
| Query Match | 32.9%; Score 465; DB 17; Length 463; |
|-------------|--------------------------------------|

Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3.

QY 33 EGNRCVEAACTADEQCQQLRSEYVAQCLGRAGWGGPGSCVRSRCRPAALRRFFARGPPA 92

Db 150 KGNNCDAKACNLDDICKKYSAYITPCTTSV---SNDVCNRKCKHALRQFFDKVPAAK 206

93 LTHALFCGCEGPACAERRRQTAPACAFSGPOLAPPSCCLKPLDCERSRRCRPLFAFQ 152

Db 207 HSYGMLFCSCRDIACTERRQTI VPCSYE--EREKPNCLNLQDSCKTNYICRSRLADFF 264

153 ASCAPAGSRDGCPEEGPRCLRAYAGLVGTVTTPNYLDNVASARVAPWCGCEASGNREE 212

Db 265 TNCQPESSVSSCLKENYADCLLAYSGLGITVMTPNYIDSSSLSVAPWCDCSNSGNDLEE 324

QY 213 CEAFRKLTTRNPCI~~LDGAIQA~~FDSSQPSVLQDQWNP 247

```

RESULT 15
US-10-872-161-12
; Sequence 12, Application US/10872161
; Publication No. US20040235714A1
GENERAL INFORMATION:
; APPLICANT: FOX, GARY M.
; APPLICANT: JING, SHOUJIAN
; APPLICANT: WEN, DUANZH
; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR
; FILE REFERENCE: A-401D
; CURRENT APPLICATION NUMBER: US/10/872,161
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: US/08/866,354
; PRIOR FILING DATE: 1997-05-30
; PRIOR APPLICATION NUMBER: US 60/015,907
; PRIOR FILING DATE: 1996-04-22
; PRIOR APPLICATION NUMBER: US 60/017,221
; PRIOR FILING DATE: 1996-05-09
; PRIOR APPLICATION NUMBER: US 08/837,199
; PRIOR FILING DATE: 1997-04-14

```

NUMBER OF SEQ ID NOS: 61
SOFTWARE: Patentin version 3.2
SEQ ID NO: 12
LENGTH: 463
TYPE: PRT
ORGANISM: HUMAN
US-10-872-161-12

Query Match 32.9%; Score 465; DB 17; Length 463;
Best Local Similarity 41.9%; Pred. No. 7.8e-32;
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;

QY 33 EGNRCVEAABACTADECCOOLRSEVYAQCLGRAGWPGSCVRSRORALRRPFARGPRA 92
DB 150 KANNCLDAKAKCNLDIDICKYRSAYITPCTTSV--SNDVCNRRKCHKALRQPFDPKVPAX 206
QY 93 LTHALLFCGCEGPACAEERRRQTFAPACAFSGPOLAPPSCIKPLDRCERSRRCRPLFAFQ 152
DB 207 HSYGMLFCSCRDIACTERRRQTIVPVCSYE--EREKPNCLNLQDSCKTNYICRSLADPF 264
QY 153 ASGAPAPGSRDGCPEEGGPRCLRAYAGLVGTVTPNYLDNVSGARVAPWCGCEASGNRREE 212
DB 265 TNCQPSRSVSSCLKENYADCLAYSGLIGTVMTPNYIDSSLSVA PWCDCSNSGNDLEB 324
QY 213 CEAFRLKLTFRNPCLDGAIOAFDSSQPSVLQDQNP 247
DB 325 CLKFLNFFKDNITCKNAIQAFNGSDVTY---WQP 356

Search completed: January 26, 2005, 13:28:26
Job time : 149 secs

